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CHAIRMAN GARY HART: The title of our hearina today is "AIDS: Past, Present and 
Future." This committee is a new one, formed by the Senate near the end of this 
year's session to coordinate the Senate AIDS-related activities and to deepen our 
understanding of AIDS and related state policy issues. This is, for those of you 
not familiar with the legislative process, this is a select committee, not a standing 
committee, which means that a select committee doesn't actually hear and vote on 
legislative bills; it is meant to be a research, fact-finding committee. The major 
time of its work is during the interim session which we're underway in right now. 
As chairman of this committee, I have four principle objectives for the next three 
months of the legislative hearinas and this is our first such hearing. There will 
be others in November and December. The four main objectives that I have are as 
follows: 
1. To learn more about the AIDS epidemic and the virus that causes AIDS; 
2. To better understand the effectiveness of existing programs, particularly 
those implemented by the State of California; 
3. To develop appropriate legislation; and 
4. To better coordinate our legislative and administrative efforts to respond to 
the AIDS challenge. 
We all know the story about the group of blind men describing an elephant, each 
convinced that the particular part of the elephant that he knew represented the whole 
animal. In the same way many of us on this Select Committee have come to the elephant 
of AIDS familiar with only one or two particular aspects of the animal. However, I'm 
confident that we will behave differently from the blind men in that story by combining 
our particular areas of experience and knowledge about AIDS into a composite picture of 
a whole animal. A picture that takes into account such varied subjects as education, 
medical care, substance abuse, prisons, public health Fractices, and a variety of 
legal issues. 
A final note, I was interested to note recently, that the eminent historian, 
Barbara Tuchman, began the research on her book A Distant Mirror intending to examine 
the effects of the plague on the entire social fabric in 14th century Europe. Although 
I believe there are important differences between the plague in medieval times and AIDS 
in modern times, I also believe there are two important similarities. Both are 
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reminders of humankind's growing but still imperfect mastery of disease, and both have 
forced society to confront our deepest fears and reaffirm our deepseated social values. 
I know we all want to help shape an AIDS policy that history will judge to have been the 
most effective health policy and the most positive affirmation of basic social values in 
these difficult circumstances. 
Since this is a new committee, before we actually get underway, I would like 
to make a couple of introductions. With our two colleagues that have joined us that are 
on the committee, Senator Marks and Senator Doolittle, but I also want to introduce the 
staff to the Select Committee; first, Kathryn Duke, who is on my right, who is a 
consultant to the Select Committee, who is on leave from the Senate Office of Research 
to provide staff to the committee. Kathryn is a graduate of UC Berkeley; has a Masters 
in Public Health, and also is a graduate of Boalt Hall Law School at Berkeley. And on 
my left is the Committee Secretary, Debra Smith; this is her first hour on the job. 
She's new to the State Capitol and I think the members and the public will enjoy working 
with Debra. 
With that in mind, we turn to today's activities. Today we will begin to get 
both specific AIDS information and the big picture of AIDS by hearing from health 
and AIDS experts. ~These people will talk about Lhe past and future of the AIDS epidemic 
and will give us federal, state an.d local government perspectives on confronting this 
epidemic. 
Our plans are to hear from four witnesses this morning. Before calling forward our 
first witness, Dr. Francis, I'd like to ask Senator Marks or Senator Doolittle if they 
would like to make any comments or have any questions before we get underway. 
SENATOR MILTON MARKS: I'd just like to make one very brief comment. I'm delighted 
that this committee has been started 'cause I think it's absolutely necessary that the 
Legislature look at the problem of AIDS, determine what can be done about a serious 
problem which affects not just one community but affects the entire community of the 
State of California. I'm not even discussing how it affects people in an international 
basis or a national basis, but obviously has a tremendous effect in California. And I 
think it is important that we discuss the issues which are of concern to· us. 
Now , Senator Doolittle and I are sitting next to each other, but we differ very 
greatly upon, I believe, upon the way in which we must solve this problem, and I think 
we must determine what can be done to resolve the problem which is of concern to all of 
us who want to do, at least I want to do it and I hope he does, want to do it in a way 
which will not cause extra problems for those who have AIDS; problems that I don't 
think it should be a criminal matter; I think it's a matter of health, and therefore 
I'm very pleased to be here. 
CHAIRMAN HART: Thank you, Senator. Senator Doolittle? ••• Okay. With that, I'd 
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like to ask Dr. Don Francis to come forward, he's our first witness. A number of us 
heard Dr. Francis on other occasions; he's a recognized expert on this disease; he's 
associated with the Centers for Disease Control and I think it'd be interesting to other 
members of the cOIIIDlittee to note that Dr. Francia has his Medical Degree from the 
Northwestern University School of Medicine; he is a Doctor of Science and Microbiology 
from Harvard University; board certified in pediatrics, and has been involved in a 
number of issues relating not only to AIDS but a variety of other health epidemics in 
this country and around the world. Dr. Francis. 
DR. DON FRANCIS: Thank you, Senator Hart. You didn't mention that I also went to 
Redwood High School and the University of California, Berkeley; you only mentioned the 
out-of-state education that I had. 
CHAIRMAN HART: We've already given too much play to Berkeley this morning. 
DR. FRANCIS: (laughter) 
CHAIRMAN HART: (inaudible) 
DR. FRANCIS: Oh, no wonder, see, I should have known. I will spend most of my 
time this morning regarding prevention, as I think that is the major issue set forth to 
us to deal with in terms of the most difficult issues. 
The issues of prevention that I -- and the way to stop this virUs from moving from 
one person to another and continuing to invade our population, I think, is critical. No 
doubt, the treatment issues are also. But one that is not my specialty and if I, best, 
I think, leave that to those individuals who deal with it. But I'd be happy to field 
questions outside my specialty subsequent to my presentation, so I will stress preven-
tion. 
In terms of prevention, all the reviews of the American response to AIDS or 
HIV infection regarding stopping its transmission, have been quite condemning. That 
comes from the Office of Technology Assessment, it comes from the National Academy of 
Sciences, or from journalistic reviews. I think it's been clear that we have NOT met 
our goals that we want, that is to decrease substantially the movement of this virus 
from infected people to uninfected individuals. 
I generally agree with that review; however, in California I'm optimistic that we 
can change that. I think the reasons for that are several. One, I have a commitment 
personally. I not only went to the University of California, but I'm a third generation 
physician in California with my grandfather a physician, my father a physician, my 
mother a physician, and now I add to it my wife a physician, all of California. 
CHAIRMAN HART: No wonder none of my friends can get into medical school. 
(laughter) 
DR. FRANCIS: And actually my parents went to Stanford. So I just thought that 
that would make the other side of the aisle here happier. 
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But not only am I committed to California, 1 cause I think California can make a 
difference. I think California, and the reason I'm here now, is that California has 
made a difference. And much of that is due to the guidance that the Legislature has 
given AIDS and the forthright approach that is taken despite being stormy, I think is 
still a true national model, and it is certainly what attracts me as a Fed to come and 
help the State of California, not only my home, but one that is clearly moving ahead. 
But the challenge that I see right now, and again I'm optimistic, the challenge is 
a political one. Scientifically, we've made tremendous progress in understanding this 
virus and we know now that transmission of this virus may not be 100% stoppable right 
now with the tools we have, but it is close to it. It is clear that we have tools that 
will allow us to stop transmission. There are more tools we need that require more 
scientific input, specifically vaccines and therapies that might help in either preven-
ting infection or treating disease once it occurs. 
But the breakthroughs· now, the difficulties now in the coming couple of years, are 
going to be policy and politically associated. And that is the challenge for committees 
like this, I think, to put the policy issues forth, ! think, as an observer of history, 
that that ability to put the policy issues of AIDS forth in a reasonable way will have 
great ramifications for our society, not the least of which will be AIDS. But when you 
look at the reviews now, in terms of what we have done as a society and the failures we 
have done in society, and the fact_ that it's government responsibility to do this, the 
whole respect for government on a relatively simple issue like AIDS will fall tremen-
dously if we do not respond, and we've got much more complex issues scientifically in 
the coming biotechnological revolution, etc., etc. If we can't deal with the relatively 
simple issues of AIDS, I think it will be a true scar. 
Now my prescription for this disease, if we indeed admit that we have· shortfalls 
in terms of prevention. I, in the middle of night last night, got up and made my 
prescription, and my prescription as a physician, is for CPR. And I add another R on 
the end of that to make it CPRR, in terms of what needs to be done. And that is, 
first the C, is to Care. I can't emphasize how much lack of interest, lack of care 
has done in terms of the AIDS epidemic; just people saying it will take care of itself, 
it'll be something simple, it'll be a quick fix, we'll deal with it cheaply, and it'll 
go away tomorrow. We have to care. 
---- -----
P, Policy. Policy based on science instead of on hysteria. Relatively straight-
forward, again, from our side in public health, but allow us to work, take off the 
shackles, provide the resources to move ahead. 
The first R is Resources. We have been shortchanged in public health from the 
beginning on this issue and it continues to be a major problem. We need the resources 
necessary to carry out the policies that hopefully groups like this put forth. 
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And the last R, a 8111811 R, is Realism. The road to this will not be entirely 
smooth. It will continue to be difficult and we must expect it to be difficult. Stand 
tall, move ahead without being battered from one pillar to the next post, and losing the 
ultimate direction of the program. Let me deal with them in terms of each individual of 
the CPRR. 
Care: We have to look at this disease in the long term. I look at this disease, 
not for me, but for my children -- that their life in California's going to be very 
different than mine. And that we have to look ahead for all the children of California; 
all the people of California, ~· in terms of truly caring, not just for our own 
individual success, whatever that field may be, in politics or science, but for · the 
society as a whole. That we have to care for the prostitutes who get infected. We have 
to care for the gay men who are infected and are going to get infected. The IV drug 
users, the hemophiliacs, and all of their loved ones, and wives, and sexual partners, 
that we indeed have to care for them, really basically and understand that these indivi-
duals, and that they are humans in this society, and truly care for their future. Why? 
There's one -- if I had to get over one statement in terms of prevention of HIV 
infection, is to give the individual the opportunity to not get infected. My kids are 
6 and 9 and they're already being started on that cpportunity. That they -- indivi-
duals, are going to take the responsibility for preventing themselves from getting this 
infection. We must give them the best of all those possibilities of opportunity. 
Clearly, as I read the polls in California, the people want it. The people want 
that opportunity. They understand it, they're willing to pay the money, they're willing 
to make the difficult decisions. The question is can we transmit that political 
will of the grassroots level, that individual will, through the political process 
and back down to the street where we can maximize the effect. That's care. 
P, our Policy. The issues of policy based on what we know about this virus are 
terribly important, instead of basing policy on what we don't know about this virus and 
fear. We know a great deal about this virus and how it's transmitted. 
One, we know that it is dangerous. It is a virus that is in a league well beyond 
the league of agents that we are accustomed to dealing with in the United States. 
Any virus that is going to kill in excess of half the people infected, is a very dan-
gerous infection. 
We know now, that from the cohorts of individuals you can, you can predict that 
a sizable proportion, much different than polio or hepatitis B or any other, it's 
somewhere in excess of 50% more than likely of individuals infected with this virus 
will develop AIDS - a 100% fatal condition. ~ is a dangerous virus on anyone's 
list. 
Two, we know about the transmission. Really remarkably well, and I want to base 
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the prevention of this virus on the transmission. It transmits effectively. maybe not 
efficiently. but effectively. through sexual activities of both homosexual and hetero-
sexual and bi.direct ionally heterosexually • through the sharing of blood • and from 
mother to infant. Those are the ways it's transmitted, and those are essentially the 
only ways that it's transmitted. We should base preventiort policies on those means of 
transmission. If there's a few exceptions hither and thither, it's remarkable how few 
there are in terms of this infection. 
We must not base the policy of AIDS prevention in the United States on 6 rather 
extreme cases of infection in the United States, let's say by blood spilling onto open 
lesions of the hand of a hospital worker. but we should base them on the 42 plus 
thousand cases that we know about the transmission. Let's be sensible and take the 
information we have and move forth. It's terribly important to stress that it's not 
transmitted outside of these settings by mosquitos, by casual contact, etc., etc., 
because that changes our entire program in terms of prevention . 
Now. important issues. We must decide in the government what we're going to do. 
And the number one is whose role prevention is. It is clearly not a good private sector 
business. Prevention of diseases falls upon the government. At a time when there's 
much interpretation that the government should be a lower profile instead of a higher 
profile. That has hurt us from the beginning of this disease and continues to hurt us. 
That defense. defense against an invading organism, is the same as the defense against 
an invading foreign invader. This is a foreign invader and we must take appropriate 
government action. 
That this does not fit well, maybe ultimately it will in terms of the HMO (health 
maintenance organization) type maintenance of health, but right now it is clearly 
a public health which is clearly a government sector of all federal. state. and local 
that needs to be supported. 
The Policy. If it is. if we accept it as a government role, what is the govern-
ment's role? I think it's terribly important to look at how we in public health use 
the government role in public health. There's two real extremes; one is the government 
responsibility for preventing the disease. and the other one is the individual's respon-
sibility for preventing a disease. 
The overnment res onsibility we take for diseases. they're by and large dangerous. 
that are transmitted through nonconsensual acts. That is. if I had bubonic plague. 
I could transmit it to you; if I had typhus and there were insects or plague and there 
were fleas in the room. it could be transmitted. The government takes responsibllity 
of finding those infected individuals and removing them from the society so they do 
not infect other individuals who do not consensually, essentially volunteer for this 
infection. 
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The individual responsibility approach is used when diseases are transmitted by 
individual, consensual acts. That is, when an individual, or two individuals, for 
infectious diseases are required to both undertake in terms of HIV transmission, either 
sex or intravenous drug use, then they are essentially volunteering for infection. In 
that situation, public health would say let's move to the individual and convince them 
through information, through motivation, and through the skills to one, if they are 
infected, not to transmit it to somebody else, and two, if they're uninfected, prevent 
yourself from being exposed to this virus. 
Now, those are two very, very important concepts. You have the government screen 
test, find the infected individual, separate them from society. And the volunteer, get 
the information, the motivation, and the skill going out to the individual. 
Now, which one of those we put in place depends on the transmission of the agent 
that we're dealing' with be it plague, movement of the government, or something 
else where we stress to the individual to take the responsibility. We look at the 
epidemiology of HIV, the virus that causes AIDS, there are both sides of this. I think 
you could say that the individual receiving a transfusion, the baby born to an infected 
mother, are not agreeing to be infected with this virus, they're not agreeing to being 
exposed. 
So we move in, especially in the transfusion setting, and the government makes a 
decision that there shall be no blood given in California that is from a donor of a high 
risk group and/or that has antibody in that blood. That blood shall not be used, it 
shall be disgarded. Very appropriate move of government to move through. 
The mother/infant issue is a little more difficult and it's just evolving in 
California. 
But, so we use the government role. But to use that role for the consensual 
transmission as has been hinted to, and in some, at least federal political circles, 
overtly mentioned, that is, to screen everybody and put them in quarantine, and isolate 
in an involuntary setting the positives from the negative. It will work -- it clearly 
will work if you do it effectively. But it would require such an expense and such a 
social disruption, that I don't think, as a public health advisor to the State of 
California, that I would recommend it. 
It would mean keeping everyone in their house for a week, let's say county by 
county by county, using police force; testing them; turning those results around; 
determining who's positive and who's negative; put the positives on one side of the 
fence and the negatives on the other side of the fence and keeping them there. We could 
do that. But it has to be done right, it can't be done half-way, because the message 
that you've given these two sides of this are very different. 
When you screen out the individuals on the quarantine side, you say the government 
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has said that there are no infected people out there. You may do as you wish. You 
may undertake risk behavior that would transmit HIV infection because there's no HIV 
infection out there. If you blessed everyone out there as being clean. 
On the individual's side, we're giving the exact opposite message. We're saying 
you must assume that everybody out there is infected. So if you're going to undertake 
the type of risk-provoking behavior that could transmit HIV, you better assume that 
they're infected, and if you choose to do it, which is up to you, you must take protec-
tive measures. So it's very different, the message, and if you confuse the public on 
what method you are using, you will confuse this message and ultimately increase trans-
mission. 
Now, the confusion on this has centered around testing. Because testing per-
forms serologic testing has a very great· role in both sides of this. There is no 
doubt that having individuals come forth to be tested, to be counseled and change their 
behavior, both if they are uninfected and if they are infected, has tremendous public 
health implications, and we encourage that. There's hardly a person in public health 
who doesn't want large, expanded use of the serologic test, to see if people are infec-
ted or uninfected because it clearly has a beneficial role in terms of decreasing 
transmission and educating individuals if it's linked with counseling. 
But what happens is, people don't realize it's the counseling that's important in 
that process, and they confuse it with the government responsibility side and say it's 
the testing that's important and ~:eating is easy; let's test everybody and get rid of 
this virus. If that were possible, I would recommend it tomorrow. 
But if you're going to test and you want to get rid of this virus, you must go 
all the way to that extreme, or you're going to buy all of Sacra~ento and put 300,000 
infected people in there and maintain them for a lifetime; away from the other indivi-
duals, and anybody coming into this now clean society by airplane, by bus, by car, 
is going to have to go through an appropriate quarantine and testing procedure before 
they'll be allowed to get into our clean California. 
If you do that, it will cost a tremendous amount of money, would be so socially 
disruptive, to have great injury on the economy and obviously, I think, is not justi-
fied, because we've already seen that the individual responsibility approach can have 
tremendous effect. 
If you look at the gay community alone, in a place like San Francisco, and indeed 
across the country now as a result of much of the work in San Francisco, you can 
see the rates of infection dropping dramatically. We are talking about 1% or less of 
infection a year by using voluntary testing. 
CHAIRMAN HART: Senator Doolittle. 
SENATOR JOHN DOOLITTLE: Doctor, are those the only two approaches that you're 
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aware of? 
DR. FRANCIS: No, there's gray approaches in between, no doubt. No doubt that 
there are grays between the whites and the blacks and that you get into a difficult 
situation when you have an individual who's infected and what you're going to do. 
That's my simplification to, I think, clarify the issue. Has it not clarified it? 
SENATOR DOOLITTLE: I was just going to observe, I'm not aware of anybody who's 
advocated the one extreme that you were talking about. I mean, it's an absurd propo-
sition to begin with. And it seems like, if that leaves us with the other alternative 
which is the status quo, that certainly is becoming unacceptable, I think, to a number 
of people. I just wondered if, if you saw any role for expanded testing, or if you feel 
content with the present situation. 
DR. FRANCIS: The whole purpose of my being here, Senator, is not to push for the 
status quo; when I finish I would hope that there would be a momentum that we cannot 
accept the status quo, because transmission carries on and that we MUST not accept the 
status quo. Absolutely. 
And that expanded testing is a very, very important part of that. But, in terms of 
the involuntary nature of it, I can tell you. I would really ask that you look at 
the data scientifically, that if you have the Big Brother approach on this voluntary 
system, then you scare the people away from the prosram and that is not without documen-
tation; that the issue of potential discrimination against individuals inappropri-
ately if we in public health want to remove someone from society who's a risk to someone 
else in an involuntary setting, that is discriminatory, no doubt, and perfectly appro-
priate. 
But it's the -- it's the fear of the inappropriate outside of the recommendations 
of public health that literally drives this virus underground, reverses the messages, 
and confuses the individuals and, I.think, ultimately increases transmission. But, I do 
not want the status quo; I didn't mean to say that. 
I think I would like a system where every person at possible risk of this virus 
would come forth, be tested, enter a program, enter counseling programs, where both the 
negatives and the positives could be convinced, as I think has been shown to decrease 
their activity, even shown in IV drug users who, although addicted to drugs and cannot 
get off of it, can indeed change their behavior to minimize HIV transmission. 
So, no, I do not mean the status quo, and I agree that there are gray areas , but 
the important aspect of this is that in california, where well over 90% of the infections 
occur in purely consensual acts where you have two people, if you can get to one of 
those people, you can stop transmission. It only has to be a SO% effective program, and 
you'll end up stopping transmission or decreasing it dramatically. 
SENATOR MARKS: I -- could I just say one thing. 
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CHAIRMAN HART: Senator Marks. 
SENATOR MARKS: As I understand his testimony; he said that unless you have a test, 
of everybody, if you're going to have testing, you should have everybody, to use Sacra-
mento as an example, 300,000 people, you have to test them all. The test that, all 
due respect, that Senator Doolittle has suggested, I do not think of the subject matter 
that he's talking about, that you're testing some people, not all people, therefore, I 
' think you've indicated rather strongly, that those tests of a partial nature are inef-
fective. 
SENATOR DOOLITTLE: Now, is that your testimony, Doctor? 
DR. FRANCIS: I think if you use mandatory testing on a partial basis, it would not 
be effective. If you want to actually test and isolate individuals, you have to test 
everyone. 
Now, all of public health and all of government, for that matter, we direct our 
money toward the highest payback, because you don't want to waste money through testing, 
or working in areas of low risk. If you have your pot that's only so full, you first 
want to take the layers of the highest priority. And so, in terms of testing, the first 
people to bring forth in testing are your highest risk groups which, right now in 
California, are gay men and IV drug users. And then you work your way down that process 
and ultimately I wouldn't be surprised if we got lower, as we got more money on the 
prevention side, that lower risk groups -- for example, mothers planning on getting 
pregnant, women planning on getting pregnant, women of the child-bearing ages, they are 
in family-planning clinics -- it would be recommended that they be tested. I think, 
again, I think you have to do this on a recommended basis; I don't think it needs to be 
done on a mandatory basis. Why? Because, right now we haven't gone through the 
maturity process of deciding exactly, in terms of government, what's going to happen to 
these individuals. Once it's clear, once there are laws to protect people against 
inappropriate discrimination who have HIV, then I think you can make broader and broader 
recommendations, and in that matter if the government so desires, to say that every 
woman needs to be screened who enters the child-bearing age to prevent perinatal trans-
mission of the virus. There's all sorts of variations on that theme, but I think the 
issue should be that this is recommended. And by and large, people recommend what their 
hysicians -- which becomes a standard in medical practice and very few people decline. 
But again, it's the aura, it's the aura, it's the negative retribution, it's 
this it's the big brother coming down with laws that you get an extra 3 years for 
this or you get penalized for that, which are a whole negative, instead of the govern-
ment working with the people to help them prevent this disease, you end up with an 
adversarial situation and I think it's terribly important to avoid that. 
The last issue under P is Policy. I think it's very important and it's been 
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shown over and over again that the ultimate control of this disease and the policy that 
needs to be tailored is tailored for the individual community at the county and commu-
nity basis; that we've had more and more difficulty at the federal and state and even 
county levels sometimes, in government in moving things through. But when you turn it 
over to the community and get the individuals who know the community and know the 
activities of that community, that you can have a tremendous effect. Again, the big 
brother versus the -- the neighbor approach. 
Let me move, then, to the first R of the CPR process which is Resources. The 
National Academy of Sciences has recommended that somewhere in the neighborhood of $5.00 
per person per year be spent on prevention of AIDS. That dollar figure will vary over 
time as we get more of a feeling of what it's truly going to cost and, and what the 
evaluations are going to be required in terms of seeing how effective the given program 
is, but I think that's a reasonable target to head for. 
CHAIRMAN HART: Is that $5.00 per year, or ••• 
DR. FRANCIS: Per person per year. 
CHAIRMAN HART: Per person ••• 
DR. FRANCIS: I think I would see that for the next 5 years until you get an 
established base and then you could have your, hopefully, your student as the kids 
come into the cohort with information as they come out of school, then it's possible 
that that can be decreased. 
CHAIRMAN HART: So on a nationwide basis we have over 200 million people so 
you're talking about an annual appropriation in excess of a billion dollars. 
DR. FRANCIS: Right. 
CHAIRMAN HART: How much, if you put all the different funding sources ~ogether, 
are we currently spending in the United States on AIDS, do you believe? 
nR. FRANCIS: It depends on state, obviously and, and right now the next year's 
budget for prevention of AIDS will be about a quarter of a billion dollars, is the 
proposal. 
CHAIRMAN HART: That's the federal level ••• 
DR. FRANCIS: Right. 
CHAIRMAN HART: ••• there are various states that are involved in AIDS programs so 
you add that in, I presume, and so you probably approach a half a billion dollars? 
DR. FRANCIS: Nationally as a result of that small amount, if you think about AIDS 
prevention today, we all think that we in public health are out there taking care of the 
people. At best we have a skeleton prevention program. And the term that is used 
repeatedly with reviews used by the National Academy of Sciences is that the entire 
program is woefully inadequate. We have only a skeleton of AIDS prevention out there 
now and the people, I think, expect a lot more and deserve a lot more. For example ••• 
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CHAIRMAN HART : 
prevention. 
The billion dollars that you're talking about, that's for AIDS 
DR. FRANCIS: Prevention alone. 
CHAIRMAN HART: And does that include research or is that just education? 
DR. FRANCIS: No, the recommendation by the National Academy of Sciences was 
another billion dollars a year annually for research. 
CHAIRMAN HART: I see. 
DR. FRANCIS: The -- as an example of this skeleton program, right now, we have 
intravenous drug users who know about AIDS, who want to stop sharing needles, who 
want to get off the streets, intravenous drug use, who want to get on Methadone programs 
where they can take oral instead of intravenous medications, and cannot do it without 
months of delay. Is that an effective AIDS prevention? 
As a result of the skeleton AIDS prevention, we have sexually transmitted disease 
patients -- clearly, individuals at risk -- who have gonorrhea, or chlamydia, or syphi-
lis, or whatever it is now, coming to sexually transmitted disease clinics and getting 
little or no information on AIDS prevention. We know, from the history of AIDS, that it 
is these patients who are the cases of AIDS tomorrow. We know that the people who have 
AIDS today have been to our sexually transmitted disease clinic and still, the sexually 
transmitted disease clinics do not have the staff to aggressively counsel these indivi-
duals as they come forth. 
We have people lining up to take testing as the climate improves and California 
looks more positive towards testing and lack of inappropriate retribution on these 
individuals, that there is a lineup for people being tested, but that process can 
take weeks before the individual actually gets testing because of lack of resources. 
We have no long-term counseling follow-up process for positive individuals and I 
think that's terribly important that that ultimately be integrated. We don't have, 
with even a patient of AIDS as reported now, we don't have a system in place now 
that his or her sexual contacts are counseled on how to avoid infection. Their ongoing 
sexual contacts, in terms of how to avoid infection from this virus of individuals we 
know, get increasingly infectious with time. 
In summary, the basics for prevention are missing. There's some there, there's a 
skeleton there, but there's no muscle, there's no skin, there's no movement, and it's 
just stattiug. In California It's far ahead, indeed, of other areas. But you can't sit 
and wait for resources at the federal level. That it is clear from Vice President 
Bush's discussion that I read in the paper about four or five days ago, as he spoke 
in San Francisco, that the federal government is going to turn more and more of the 
responsibility for these kinds of activities on the states. Now, unfortunately, with 
AIDS it was caught right in the middle of this transition and that the classical federal 
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money, federal policy coming down through states to local health departments for the 
prevention of disease has changed, and AIDS got that change right in the middle and has 
made it very difficult. So I think the expectations of where the monies come from -- I 
think you have to be very careful in terms of the future of expecting too much from the 
federal government. 
The last R is Realism. That we have to be realistic. That the system is not going 
to be perfect. That there are going to be individuals who are out there who don't care 
about infecting other people. That's a very important issue that'll come up. What do 
we do with a known infected person who's still having sex? Again, if we put the 
responsibility on the individual instead of the government, we hope that the individuals 
with whom that individual comes in contact would actually prevent transmission by 
not having sex with the individual. 
The other thing in terms of realism that is ao difficult for us to deal with, and 
it's an issue that has come up again and again and again, that there are homosexual men 
in this society, there are intravenous drug users in this society, there are people 
having heterosexu--, sex in this society 1 and the government program that tries to 
intervene in the transmission of HIV by all of these individuals is not advocating any 
of these practices. We are not advocating heterosexual sex; that's not our role in 
government. We are not advocating homosexual sex; that's not our role in government. 
What our role in prevention in the public health sector is to recognize that these 
risk factors exist and that we must deal with these on a very realistic level. It is 
clear in my mind that homosexuality has existed for a long period of time, will continue 
to exist as long as man will be around and we must recognize this. We must be realistic 
that these individuals are here in society, are part of society, and we must care for 
them as we do other parts of the society. But we must realize that we're not going 
to please everybody. If we try to have an AIDS program that will prevent all of us from 
getting nasty letters on our desks because we talk about anal intercourse or vaginal 
intercourse or something that offends people, then I'm sorry that it offends some 
people. But some of that is going to exist and there are many more offensive things in 
our everyday life -- we just have to deal with reality and move ahead with it. We 
cannot expect to have AIDS prevention programs that do not mention sexual activity and 
intravenous drug use and teach these individuals how to avoid HIV infection should they 
want to practice this. 
The other thing that I think is a, is a great deal of concern in terms of 
of reality is time. That with all of our restrictions in government spending, not to 
mention allocations, like getting of money, allocating and actually spending, that a 
year or two can go by very, very quickly between the time that you people make resources 
available and the actual individual is hired on the street. That any decisions you make 
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you have to realize that you're making tomorrow's decisions and yet we needed a program 
two years ago. 
That is the end of my CPR and I, again, restress what Senator Doolittle says, and I 
think, I stress, nicely, that we do: we should not be happy with the status quo. 
That we must move ahead with a scientifically-based, agressive program for HIV preven-
tion. 
CHAIRMAN HART: Okay, thank you, Dr. Francis. Senator Marks. 
SENATOR MARKS: Senator Doolittle's sitting right next to me so he can disassociate 
himself with my comments, if he wishes to do so; I'm sure he will. As I understand 
his bills -- basically his bills call for partial testing of some people. Some people 
would be tested, others wouldn't. Now, what effect, if any, will that have by partial 
testing? 
SENATOR DOOLITTLE: Let me just interject since we don't want to set up a straw man 
we have to knock down. 
SENATOR MARKS : Okay. 
SENATOR DOOLITTLE: The bills, with the exception of criminal acts where AIDS may 
be transmitted or in involuntary settings like state prison or confinement, long-term to 
mental health facility, are basically prescribed, voluntary, routine screening at 
certain intervals; it is not mandatory. So, you know, I think that you should understand 
that as you address the question. Reasons I do not want to get involved with ••• 
(inaudible due to cross-talking) 
SENATOR MARKS: ••• disagree with you, I don't think that is the-- those are 
the bills, but, if you say they are the bills, we'll -- I'll look at them again. 
DR. FRANCIS : I know that the members of this committee are intelligent, able 
individuals who are know AIDS very well, and that a concensus can be moved along 
that widespread use of voluntary testing should be; that's what one Senator wants, 
certainly what we want in public health, if you can protect the individuals who get 
tested from everything from losing their jobs to having their house burn down, then I 
think people will come forth and I don't think anybody will disagree with it. 
SENATOR MARKS: You're telling me, Senator Doolittle, that your bills are volun-
tary, they're not compulsory at all? 
SENATOR DOOLITTLE: With the stated exceptions, they're voluntary. The individual, 
if he chooses not to be tested, will not be. But in the absence of his objection, the 
doctor may test him just as he can test an individual for any which number of things 
today. 
SENATOR MARKS: And they're, and they're confidential? 
SENATOR DOOLITTLE: It would be disclosable to other medical personnel involved in 
the treatment of the person and to the public health official. To that extent, such 
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disclosures today would violate California law. 
SENATOR MARKS: And you're supportive of the present California law? 
SENATOR DOOLITTLE: I am NOT supportive. I am actively seeking to repeal the 
present California law. 
SENATOR MARKS: That's the point that I'm trying to make, that uh, ••• 
SENATOR DOOLITTLE: But then your objection, Senator, doesn't go to the voluntary 
routine screening. It would go to the issue of modifying the confidentiality. And 
perhaps modifying the prior written consent, which are, you know, two issues that need 
to be discussed. 
SENATOR MARKS: Well, the issue that I've been trying to raise is whether or not 
your bills, which I think call for not complete testing -- partial testing, if I under-
stand that correctly, I think I do; those bills which call for partial testing will 
help. Are they not partial testing? 
CHAIRMAN HART: Well I think, I mean, we're not here to debate ••• 
SENATOR MARKS: I 1m not trying to debate ••• 
CHAIRMAN HART: Senator Doolittle's bills at this point ••• 
SENATOR MARKS: I'm trying to find out ••• 
CHAIRMAN HART: I think, you know, maybe we ought to look at those bills at some 
appropriate time, get a proper understanding of what's in the bills. We've got dif-
ferent representations of what's in the bills, but we do have other witnesses. I 
mean, I want to give the members an opportunity to, in a sense, make their positions 
clear, but this is not the forum to spend a great deal of time debating bills that have 
either already passed or defeated this House of the Legislature. 
SENATOR MARKS: What I was trying to do was --I'm not trying to debate his bills, 
we' 11 have. an opportunity to do that again, but, I was trying to find out whether 
or not the testing which is called for by this, these bills, if I'm understanding 
correctly, which is a partial testing, is from this doctor's standpoint, satisfactory. 
Now, maybe I don't understand the bills, I think I do. 
DR. FRANCIS: I think that if you're going to do the large scale screening and 
quarantine, it has to be complete. Targeted from then on is targeted by, by what you 
have in your prevention pot. 
CHAIRMAN HART: The concern of the testing, as I understand it, it's like these 
services that were established to -- so you can go get a card, so you can tell your 
potential sexual partner that you got tested two weeks ago, that that's terribly 
irresponsible, because there's no assurance. And your point is that if you're going 
to test with the idea of giving people some degree of certainty or assurance, then 
you better do it 100% of everybody, and properly quarantine people who test positive, 
and if you're not willing to do that then you're giving false senses of assurance and 
- 15 -
potentially going to lead to increased transmission. Isn't that the point? 
DR. FRANCIS: If it is the government heavy-handed approach. What I would agree 
with in Senator Doolittle's proposal is that if you put voluntary routine or voluntary 
testing together with counseling, where you change behavior on the personal approach 
towards AIDS prevention, then the testing has a large role and I think should be 
readily available rapidly for people who choose to use ·it. So the testing cuts both 
ways. The problem as I see it is, if you have the Big Brother "We're going to take care 
of you once you are infected with this virus" approach, then you will not have the 
individuals coming forth that you need to be tested. That is very clear from the data. 
That in California's primarily gay men, will run from the testing program. And what 
we're trying to do and what the gay community is trying to do, by and large, is to 
encourage people to change their behavior, and testing is a tool linked with counseling 
to do that. 
SENATOR DOOLITTLE: And that's the premise of our bills. The bills don't address 
quarantine. 
mentioned. 
Nor do they address mandatory testing outside of the exceptions that I 
DR. FRANCIS: I think the issue of testing is, it cuts across, gets to be a very 
heated one, but the issue gets confused because we're trying to think about which 
side of this approach we're using. If we're using the voluntary approach linked 
with good, top of the line, modern behavioral science in terms of counseling, I don't 
think anybody in public health would object to having testing on a large scale avail-
able. The test for the human immunodeficiency virus is a part of our social nature ••• 
(void in tape) ••• ~ehavior and needn't be tested at all. They know that; they needn't 
come forth. But they're individuals who, through various programs, are found to -- this 
could be useful to them and certainly could be useful in terms of medical care. Now, I 
think that's getting more and more solid, that there is going to be a desire for people 
who possibly have been exposed to this virus to come forth to be tested, because early 
intervention medically is probably going to prolong their quality of life and that's 
going to be very important in the future. I don't think we're going to have to en-
courage this test. We're doing 12,000 tests a month in California; it's not a matter of 
encouraging the testing, it's a matter of making the program first class so it has the 
_______ ma_ ximum effect, which is not just testing people. That's the naive thing; if you just 
recommend testing and say that' 11 take care of AIDS, that is not the truth; I don't 
think anybody here recommends that. You have to put it together with a rational program 
of counseling individuals to avoid high-risk behavior. 
CHAIRMAN HART: Thank you very much, Dr. Francis. 
Our next witness is Dr. Neil Flynn, who's currently the Director of the Clinic for 
AIDS and Related Disorders at UC Davis Medical School. He's an Associate Professor of 
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Medicine at UC Davis; involved with the treatment of numerous AIDS patients; is moni-
toring the spread of HIV infection among IV drug users in Sacramento; Senator Seymour 
and I heard Dr. Flynn's testimony last week in San Francisco on that issue. He also 
will be monitoring the administration of AZT to inmates at the Vacaville State Prison; 
and is preparing for an AIDS vaccine trial with people infected with HIV but without 
other disease symptoms. Dr. Flynn, welcome. 
DR. NEIL FLYNN: Thank you, Senator Hart. 
My charge this morning, in a half an hour, and I realize that that is no longer 
possible, but we'll try to keep it to 20 minutes, here, is to talk about (void in 
tape) ••• described. That those who become infected with this virus have a high proba-
bility of eventually developing full-blown AIDS. If we look at studies that are 7 or 8 
years old now, 40% of the people that were infected 7 years ago have now developed 
full-blown AIDS. And another 30% have developed AIDS-related complex; they are ill. 
Ill enough that they can no longer carry out their usual daily activities. So we're 
looking at over 2/3 of individuals who were infected 7 years ago, being ill. 
CHAIRMAN HART: Senator Doolittle. 
SENATOR DOOLITTLE: Doctor, is it your belief that that percentage, as time goes 
on, will continue to increase? I've read, d~pending on some scientific and medical 
experts, that if given enough tfme that figure would be virtually 100%. 
DR. FLYNN: It may come close. I don't say that because of my respect for my 
patients' hope, that they may have a little bit of hope. That there may be 10 or 
20% of individuals who are able to resist this virus life-long. We know that's true of 
all other viral diseases and all other infectious diseases; there are individuals who 
can resist genetically, who are in some WilY genetically resistant to the virus. But 
yes, it's going to approach 80 to 90% who eventually develop AIDS in the absense of good 
treatment that will slow down the progress of the infection. 
SENATOR DOOLITTLE: Do the -- from your knowledge and experience, do the people 
that have ARC, do those always, then, progress to AIDS eventually? 
DR. FLYNN: Well, we haven't observed them long enough, but most of them do. 
People who have full-blown ARC, who are quite ill, and have any one of four or five 
particular symptoms, over half of those people will have AIDS within 18 months. 
And the other half, within probably 2 to 3 years. But, most of the ARC individuals 
will develop AIDS. 
SENATOR DOOLITTLE: Thank you. 
DR. FLYNN: Which brings us to the point that in California, with perhaps 200 to 
300,000 people infected, we can look at the next 10 years as half of those individuals 
developing full-blown AIDS. At least half of them and another 1/3 developing symptoms 
of ARC, becoming ill. 
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Now there are a number of things that happen to an individual throughout the 
progress of their infection. For a long time, perhaps 2 or 3 years, 4 years, the 
individual has no symptoms whatsoever, other than perhaps enlarged lymph nodes, which 
are swellings in the neck or under the arms. If we look at their laboratory tests, 
however, we see that the lymphocytes that are in their blood begin to fall. Even within 
the first 1 to 2 years of infection, there is some small fall off, die off, if you 
will, in the lymphocytes, and that continues for the duration of the infection on until 
AIDS -- full-blown AIDS, those individuals have very, very, very few lymphocytes of the 
type that we assume help with immunity left. They are almost all gone. 
Now the patient goes through a complex process, both psychologically and physical-
ly. As the immunity goes down over 3 or 4 years, the individual is subject to infec-
tions that ordinarily don't occur. Individuals may get yeast in the mouth without 
having taken an antibiotic; they may get what are called shingles, which is chicken pox 
come back in a nerve, very painful; they may have fevers and night sweats from time to 
time; lose weight and gain it back; have periods where they're severely fatigued and 
then recover again for a few months at a time. But eventually, most of these indivi-
duals go on to develop full-blown ARC, AIDS Related Complex. And this is weight-loss, 
fatigue, diarrhea, 8 or 10 liquid stools a day, which makes it very difficult for an 
individual to hold down a job, particularly if they've lost 20 pounds, feel fatigued all 
the time, have nearly continuous diarrhea, etc. 
In addition, the effects of the virus on the brain produce a depression syndrome, 
and we see depression in individuals even before they are aware that they have the 
virus; even before we make a diagnosis of infection of the virus. One can imagine 
that after we've made the diagnosis of infection with the virus, an individual has 
a right to be depressed for a year or two or longer because that individual is aware 
of what's coming. But even before we make that diagnosis, there is depression. The 
virus infects the brain ••• 
CHAIRMAN HART: Always, or sometimes, or usually? 
DR. FLYNN: Most of the time, Senator Hart. Probably 70-80% of the time we can 
find evidence of infection in the brain, either at autopsy or at brain biopsy if we 
are in a position to take a brain biopsy for some other reason. 
SENATOR DOOLITTLE: I have a question on that, Mr. Chairman. Does that happen 
before there are other manifestations at -- for example, a person that becomes infected 
with HIV, but before there's objective manifestations of ARC, or something ••• 
DR. FLYNN: It can. There can be depression and/or loss of some mental func-
tions -- very, very mild dementia that can only be picked up on very sophisticated 
testing such as IQ testing and things like that. There is some very mild changes. 
SENATOR DOOLITTLE: Anything that, from what we know about, that would say, impair 
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judgement or that kind of thing? 
DR. FLYNN: As it progresses, in some people, yes, it will impair judgement. 
Depression impairs judgement as well as the loss of intelligence and intellectual 
capacity. Both of those things will impair judgement. 
CHAIRMAN HART: Doctor, let me make sure I understand -- you're saying, if I --
correct me if I'm wrong, that this depression comes before people know they have the 
disease and did you say 70-80% of the cases? 
DR. FLYNN: No, the depression is less than that before the disease is diagnosed, 
perhaps 20% or 30%. My statement about 70-80% is that the virus involves the brain in 
that percentage of people infected with the virus eventually. 
CHAIRMAN HART: So the depression comes before knowledge of the disease in 20% 
of the cases and in 70-80% the virus does affect ••• 
DR. FLYNN: ••• affects the brain. Right. Either to produce the mood changes such 
as depression; we've seen patients with psychosis who had developed paranoid schizo-
phrenia and we've had other patients who have become demented. And that is maybe the 
only manifestation of their infection for a long time. It may be months to years before 
they develop infections or cancer from the AIDS virus. 
CHAIRMAN HART: Senator Marks. 
SENATOR MARKS: You may have asked this question before, but those who get ARC --
what percentage of them eventually get full, the full degree of AIDS? 
DR. FLYNN: The majority of them will have AIDS within 18 months. Now there are 
some who have gone 2 or 3 years with ARC and still don't have full-blown AIDS. But if 
you look again at their blood parameters, their lymphocyte counts go down continuously 
during that time and die off. 
CHAIRMAN HART: So, if someone has ARC, will they eventually get full-blown AIDS? 
DR. FLYNN: Probably. 
CHAI~~ HART: But we just don't know yet, because the disease is ••• 
DR. FLYNN: We don't know what percentage. And again, to remove hope from 10, 20, 
or 30% is not good for people. We have to ••• 
SENATOR HART: You mentioned ••• 
DR. FLYNN: ••• hope that they will escape full-blown AIDS. 
CHAIRMAN HART: Well, you mentioned also, I wanted to make sure I understood this 
term, that people have ARC-related symptoms. I don't quite know what that means. 
If someone has ARC-related symptoms, does that mean that they ••• 
DR. FLYNN: ••• have ARC. Yeah, if you add up a few of the symptoms, say, 3 or 4 of 
them -- diarrhea, fatigue, weight loss -- and a person has all of those, we would call 
them ARC. They have ARC. AIDS-related conditions or AIDS-related complex. 
SENATOR DOOLITTLE: Are those in conjunction with a positive HIV test? 
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DR. FLYNN: Usually, yes. Yeah. 
CHAIRMAN HART: Senator Marks. 
DR. FLYNN: ••• in very few exceptions, there are individuals who have a nega-
tive test , but, who are carrying the virus. 
SENATOR MARKS: I'm not sure I understood your answer to the question of Senator 
Hart. If 10 to 20% will not get AIDS? Is that what you're telling me? Or you ••• 
DR. FLYNN: We ' re ••• 
SENATOR MARKS: Or you ••• 
DR. FLYNN: We're hoping. The studies are not long enough, Senator Marks, to know 
what percentage wi l l eventually develop AIDS. Remember that we've been studying 
the diseas~ for only 8 years now. And we've really had scientific data going back 
to only about 1979, 1980. 
SENATOR MARKS: So you don't have enough information to know whether or not that 
is so, but it is a possibility ••• 
DR. FLYNN: ••• that some will escape. 
SENATOR MARKS : Some will escape it. 
DR. FLYNN: Yes, sir. 
SENATOR MARKS: Thank you. 
SENATOR DOOLITTLE: Can I ask one related question, something that ••• 
CHAIRMAN HART: Senator Doolittle. 
SENATOR DOOLITTLE: ••• that he mentioned, I just wanted to clarify. We say we 
discovered AIDS in 1981, but you, with the medi-scientific community, knew they had 
something they didn ' t understand related to this that went back beyond that, isn't that 
right? Back into '79 -- doesn't that go back even -- aren't there cases that they're 
thinking that they saw even in the late 40's, maybe, that turned out to be this? 
DR FLYNN: Well, it's possible. That data is still suspect, but we can trace 
antibodies back to 1976 in the United States. 
SENATOR DOOLITTLE: And then -- and Africa would go back beyond that, wouldn't 
it? 
DR. FLYNN: Uh, back to the early 70's. And there are isolated instances in· 
the medical literature of people who look like they had AIDS in the SO's and 60's. In 
that particular article I reviewed for publication and the journal decided not to 
publish it, so, we will have to see whether we can trace it back further. 
SENATOR DOOLITTLE: Thank you. 
DR. FLYNN: Now, all along the way the individual who's infected with the virus, 
once they find out, suffers the psychological effects of believing or feeling that 
they will eventually get AIDS. Most of these individuals, since they're high-risk 
individuals, have seen either friends or lovers or someone else die of AIDS, that · 
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is very close to them. So they know what AIDS is about, and they internalize it and it 
becomes a cloud, if you will, over their futures, and those individuals require a great 
deal of counseling and psychological and psychiatric help to become functional again. 
It is as if you members of the panel here were told that you have about 4 or 5 years to 
live. You have a disease that will kill you and integrate it into your lives. So 
that's another aspect that these patients go through as they become ill. They know 
what's in store because they've seen it in their friends. 
I've mentioned to you the progression of the disease that, over time, it may be 
inexorable; that all individuals may eventually develop full-blown AIDS. Some problems 
of caring for people who become ill with the virus, ARC and AIDS; we have difficulties 
in finding resources in the community for those individuals. If they are completely 
disabled, at the present time, we often rely on volunteer help. The AIDS foundations 
in various areas provide a tremendous amount of volunteer help. But in San Francisco, 
for instance, those agenci es are losing their volunteers because the volunteers are 
burned out. They have been working with the disease for 4 or 5 years, they've been 
through numbers and numbers of their clients dying and they are burned out. They 
can't stand it anymore, particularly since many of them are infected themselves and 
don't want to be shown the future over and over again for themselves. So we'll be 
facing a crisis in home care, we already have a crisis in some areas of home care and in 
skilled nursing facility care. 
Yesterday one of my patients died at home after a 2 1/2 year illness with AIDS. 
At his bedside were 4 volunteers -- hand-to-hand counselors, his parents, his physi-
cians, a physician as sistant , all the people who had grown to love this man over 2 1/2 
years. He was a fortunate man. He had all of these people available. Other patients of 
ours don't have those resources available. They have no family; their lover or signifi-
cant other has left because they have AIDS and they can't deal with it and those indivi-
duals are left for the system to cope with. Frequently we have to keep them in the 
hospital longer than would be necessary. We may go 4 weeks, 5 weeks, 6 weeks in the 
hospital when all that was really necessary was 1 week because we can't find a place to 
put them. They're not strong enough to have their own apartments; no skilled nursing 
facility in the Sacramento area -- and it's the same in Los Angeles and San Francisco 
with rare exception -- will accept an RIV-infected individual. And so acute care 
--------nospitals such as UCD or San Francisco General or Los Angeles County have to keep these 
patients much longer than necessary. Now that translates into a Medi-Cal bill; UCD does 
receive administrative days for these individuals at a reimbursement rate of $200 a day 
where the ordinary skilled nursing facility rate is $40 per day. So it costs 5 times as 
much to warehouse those individuals in our hospitals as put them in skilled nursing 
facilities. 
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CHAIRMAN HART: The position of skilled nursing homes in not accepting AIDS pa-
tients; is that good public health policy or is that ••• 
DR. FLYNN: No, it's not. It's a very good question. It is not a -- the indivi-
duals will not spread the AIDS virus within their skilled nursing facility. There do 
have to be increased infection control procedures carried out in those facilities and 
they cost extra money . But there's no reason, no logical reason, that individuals can't 
be placed in a skilled nursing facility with an upgraded infection control and education 
of the nursing staff. It is not a problem ••• 
CHAIRMAN HART: Would that be preferable than just having a sort of segregated 
skilled nursing unit for AIDS patients? 
DR. FLYNN: I don't know the answer to that. The problem with an area like Sacra-
mento, even with a million people, we have need for between 5 and 10 beds ·today, is 
all. And you can't run a profitable skilled nursing facility on 5 or 10 beds; it 
needs to be up in the hundreds area. Los Angeles and San Francisco, yes, it is a good 
option. 
CHAIRMAN HART: Senator Doolittle. 
SENATOR DOOLITTLE: I was going to ask, what do you believe would be the reason 
that these facilities aren't accepting the patie~ts? 
DR. FLYNN: Money. It boils down to reimbursement. 
SENATOR DOOLITTLE: What, what, it is what? 
DR. FLYNN: Money. Reimbursement from Medi-Cal. 
SENATOR DOOLITTLE: Is it true that caring for an AIDS pa-••• I don't know how it 
compares to some of the other serious problems they face, but I'm of the impression it 
takes more care t han the normal situation. 
DR. FLYNN: It does and skilled nursing facilities take a broad range of patients, 
all the way from those who are ambulatory and require very little care to the very 
high-care individuals. They try to keep their patient mix down toward the ambulatory 
end and so they try to keep out the more severely ill. Not just AIDS but all types of 
disease. AIDS is a specific example of being severe. And once they see that, it is 
not profitable for them to take those individuals. 
CHAIRMAN HART: Senator Marks. 
SENATOR MARKS: These -- this is Medi-Cal? These people are under Medi-Cal? 
DR. FLYNN: The majority of my patients are. I see a 
the city, and all of them with few exceptions, are Medi-Cal. So, in most cities, about 
40 to 50% of AIDS patients eventually become Medi-Cal. 
SENATOR MARKS: Now, these people who will not accept the care of the people; 
they have the authority to do that? 
DR. FLYNN: Yes, they do. They can reject ••• 
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SENATOR MARKS: On what, on what ground rules ••• 
DR. FLYNN: ••• any patient that they don't want and accept any patient that they 
want. Medi-Cal will reimburse at $40 per day, and we've worked through with our nur-
sing homes here in Sacramento, that at a $100 a day they can break even or even come 
out a little bit ahead. 
SENATOR MARKS: I'm not suggesting what we'll do 'cause I have to think about 
it, but if we were to adopt legislation that would require them to take patients ••• 
(void in tape) 
DR. FLYNN: (void in tape) ••• more care of the patient. 
SENATOR MARKS: What about the people's ability to get insurance? Are they very 
drastically affected? It's my understanding, from a number of people who have talked to 
me, that oftentimes if they're working, their insura-, and they have insurance that 
is being paid for by their employer, their insurance ends. 
DR. FLYNN: If they have been enrolled prior to the time that they are found to 
be HIV positive, the insurance company will continue them. If they try to get new 
insurance health care or life insurance after it is known that they are positive, or if 
the insurance company or employer finds out that they're positive, they're often denied 
health care insurance. 
SENATOR MARKS: Are there other diseases that you can think about where places 
like -- places refuse to take patients like they do not take people who have AIDS or ARC 
or other ••• 
DR. FLYNN: There are other ••• 
SENATOR MARKS: What other diseases are there? 
DR. FLYNN: There are instances in my own practice of elderly people who are bed-
ridden and require a great deal of care to prevent bedsores that nursing homes don't 
want. They're high-care patients, and if the nursing home can fill with a lower-care 
patient, it's to their advantage to do that and most of them are full in Sacramento. 
There is a waiting list for beds in Sacramento. So they're able to turn down the 
higher-care patients . 
SENATOR DOOLITTLE: Senator Hart and I just came fr-, well you -- we all came from 
a CMA conference about uncompensated care problems. This certainly ••• 
SENATOR MARKS: We did. 
------------------
SENATOR DOOLITTLE: ••• says the same thing. 
SENATOR MARKS: Well what, if anything, would you recommend to make certain that 
facilities such as this take people. 
DR. FLYNN: Become available? 
SENATOR MARXS: I beg your pardon? 
DR. FLYNN: Become available ••• 
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SENATOR MARKS : Yes. 
DR. FLYNN: ••• to these patients? My recommendation would be to increase reimburse-
ment for these patients to a level that skilled nursing facilities can break even 
on it; somewhere between 80 and $120 a day. 
SENATOR MARKS : Thank you. 
SENATOR DOOLITTLE: What is the, may I just ask, Mr. Chairman, what's the rate 
for primary care hospitals; what do they get reimbursed from Medi-Cal? 
DR. FLYNN: Well, we have looked at our reimbursement versus our charges today; 
if we charge $100, we get reimbursed about $40 from Medi-Cal. We can probably break 
even somewhere with our volunteers and aides, we can probably break even somewhere 
around 55 or $60. So we take a loss, the University of California Davis Medical Center 
takes a loss on every AIDS patient and virtually, other than DRG's, on virtually 
every Medi-Cal patient. 
Some other problems that these individuals suffer; testing, as you mentioned, if 
they are tested and found positive, they need to keep that secret if they're going 
to become employed, if they're applying for a new job or for insurance and many times 
they do. Because the other option is that they will be denied both employment and 
insurance if they are known to be positive . So, the effects of being HIV infected are 
both psychological, they are socia. , they involve employment long before the individual 
becomes ill and then after they become ill, they involve finding resources which often 
aren't available, and then trying t o manipulate those resources. It's very difficult for 
our patients to manipulate their Social Security and Medi-Cal to the extent where they 
can survive in their day-to-day living. Another problem that we have had is the share-
of-cost for Medi-Cal. Our patients are usually getting by on a total of about $550 a 
month on Social Security and they are asked to pay $200 a month of that for share-of-
costs for Medi-Cal and one can live in Sacramento on about $350 a month but it is 
in destitute circumstances. One can have a very small apartment, a bachelor apartment, 
and survive food-wise; no transportation, very little entertainment, so on. So most of 
my patients become relatively destitute before they die. And their standard of living 
goes way, way down. 
Some other issues that I was asked to comment on was the problem of vaccine and 
AZT. Vaccine development is going apace in California as well as nationally; Califor-
nia, I think, is way out ahead in the Legislature having provided some liability insur-
ance in a way to vaccine developers. No vaccine is going to be 100% effective. The 
vaccine is going to reduce the risk of infection but not eliminate it. So we're going 
to still have to have the education prevention programs that Dr. Francis alluded to. A 
vaccine, a good vaccine, is 80% effective, and if we were to be able to develop one at 
80% effective, we would be very, very happy. 
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SENATOR DOOLITTLE: Is that about-- let's say the polio vaccine would be ••• 
DR. FLYNN: Polio is that or a little bit better. Polio is slightly better and 
relies partly on the mass immunization effect. If one iMmunizes the entire community 
then the virus doesn't get a chance to start. And that effect probably has some effect 
in AIDS as well. It will certainly·slow the spread of it; of the virus heterosexually. 
But I don't think we can expect a perfect vaccine, and so, one will still have to 
contend with education of prevention for the virus. 
AZT is a major issue, which you'll be facing in the next few years. It looks 
like AZT is effective. It slows down the process of ARC to AIDS. Individuals take 
longer to develop AIDS, they are less ill, they are more functional, when they're 
receiving AZT. AZT prolongs the lifespan of people with AIDS, with full-blown AIDS, and 
they feel better that last year, year and a half of life. We don't have the information 
yet, on whether AZT slows down the progress from no symptoms but infected to AIDS or 
ARC. We just don't have the data; it will probably be available next summer. My 
impression is that AZT will work there as well; that it will slow down the progress of 
the disease all along the way. So, it becomes almost a standard of care, if that's 
true, for those who can tolerate the drug to take it. And that means literally, thou-
sands and thousands of Medi-Cal and medically indigent individuals needing the drug 
within the next year of two. In Sacramento County alone, if we were to do widespread 
testing among high-risk individuals, we would probably find around 2-3,000 infected 
individuals in Sacramento County today. Theoretically ••• 
SENATOR DOOLITTLE: Now ••• 
DR. FLYNN: Yes. 
SENATOR DOOLITTLE: Excuse me, I was going to ask if I could address -- 2-3,000 
if we did the widespread testing amongst high-risk groups and we have identified, 
right now, how many do you recall? 
DR. FLYNN: Oh, I'd only estimate that we probably have 7 or 800 identified in 
Sacramento today through all the various programs. It may not be quite that high. 
So Medi-Cal and counties are going to be faced with providing AZT to infected indivi-
duals. AZT costs, currently, $10,000 per year -- to provide $10,000 per year per 
patient. 
SENATOR DOOLITTLE: Is part of that cost the -- to deal with the side effects for 
~those people who are infected? 
DR. FLYNN: A small part. About 10 or 20% of that cost is to deal with the side 
effects. 
SENATOR DOOLITTLE: How many do have; the side effects are nausea, and some people 
have to have blood transfusions, right? 
DR. FLYNN: Correct. And we believe that to be dose-related. We think that by 
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reducing doses, we can get some benefit to these patients without the severe side 
effects. The drug is new, and we won't know for several years whether that's true. 
So ••• 
CHAIRMAN HART: Doctor, could I ask -- you mentioned that it's your hunch that AZT 
will slow the process all along the way. 
DR. FLYNN: Yes. 
CHAIRMAN HART: Is there a possibility that AZT would prevent people who are HIV 
positive from getting ARC or AIDS? 
DR. FLYNN: It's not my belief that it will. It will simply slow the progress. 
Now, there it may tip the balance for a few to such a long time that they die of 
other causes before they develop AIDS. 
CHAIRMAN HART: And the cost, you said, of AZT is $10,000 per year ••• 
DR. FLYNN: Approximately 10,000. 
CHAIRMAN HART: As we have more and more people who will become sick, will that 
drive the cost of AZT up? 
DR. FLYNN: It may drive it down. If it's able to be synthesized, and Burroughs 
Wellcome, and other pharmaceutical companies are working on synthetic AZT that will 
be less costly. Currently it's derived from a nat•Jral product that's in relatively 
limited supply. So hopefully, syn~hesis will help. It's still going to remain expen-
sive. 
CHAIRMAN HART: Is this aforegone -- I mean it's -- if it's in limited supply and 
you don't develop the synthetic product, then the price ••• 
DR. FLYNN: Then the price will remain high. 
CHAIRMAN HART : ••• will go much higher, won't it? 
DR. FLYNN: Yes, it may. It's already very high ••• 
CHAIRMAN HART: What are the prospects of getting the synthetic. Does that look 
pretty good? 
DR. FLYNN: I think they're pretty good within a few years. But that leaves us in 
Sacramento County, if we were to identify all of the infected people, with 3,000 people 
costing $10,000 a year, and over half of those people being either medically indigent 
or on Medi-Cal; that's a huge amount of money for a county the size of Sacramento. 
And medically indigent funds for the county of Sacramento cannot, at the present time, 
----
sustain that kind of additional cost. They would have to take resources from other 
programs provided that ••• 
SENATOR DOOLITTLE: So that would be what, about 30 million dollars, then? 
DR. FLYNN: 30 million dollars a year for a county the size of Sacramento, yes. 
And the current medically indigent funds are only about 120 million for that county. It 
would be putting an additional 10-15% for medically indigent treatment of HIV. 
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SENATOR MARKS: If you, uh ••• 
CHAIRMAN HART: Senator Marks. 
SENATOR MARKS: ••• take AZT and you're under Medi-Cal; your doctor puts in a claim 
under Medi-Cal for it? 
DR. FLYNN: Correct. 
SENATOR MARKS: The state has to pay it? 
DR. FLYNN: Currently the state will pay for AZT in people with AIDS. We don't 
know yet whether we'll get reimbursed for ARC. We think so. We will not get reimbursed 
at the present time for asymptomatics, the ones who are infected but have no disease 
yet. 
SENATOR MARKS: But if they have the disease, the state must pay it. 
DR. FLYNN: That's correct. Medi-Cal pays it. And all of my AIDS and ARC patients 
are on AZT. We lose perhaps 10-20% to side effects; very low number to side effects. 
SENTOR MARKS: Is AZT made by one company? 
DR. FLYNN: It is currently by Burroughs Wellcome. They are also licensing another 
pharmaceutical company to produce it because the demand is so high that they can't 
keep up with the demand themselves. 
SENATOR MARKS: How was AZT developed? l mean, how -- was it approved by the 
federal authorities --how ••• 
DR. FLYNN: Yes, AZT ••• 
SENATOR MARKS: ••• how many years did it take? 
DR. FLYNN: AZT has been around since the mid-60's on the shelf looking for a 
home. And like many other drugs, it has been pulled down from the shelf and tested 
against the AIDS virus and found to be active. From that point on, it took about 3 
years for it to become available. The FDA speeded up the process of evaluation of that 
drug. 
SENATOR MARKS: I'm not suggesting that you would tell us or that you would do 
it, but are there some -- is there medicine of some kind that's not been approved that 
you're using? Or •• • 
DR. FLYNN: Not that I've tried ••• 
SENATOR MARKS: ••• or others are using; I'm not saying that you're doing some-
thing that's improper. 
-----------~R:---FL YNN :--- Yes. 
SENATOR MARKS: Others may be using. 
---------------
DR. FLYNN: There are several other drugs that many people are using, and my 
philosophy for my patients is to try to discourage that unless they're taking AZT. I 
know AZT does something, but I don't know about the others. If they're taking AZT and 
they want to add something else, I will monitor them for it. I don't prescribe it, I 
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don't advocate it. There are a number of drugs that need to be evaluated, and they need 
to be evaluated more quickly than they are currently. 
SENATOR MARKS: But I mean, is the federal government, which I gather does the 
one -- does the approval of drugs -- is their process a very slow one and too slow? 
DR. FLYNN: Well, they've speeded it up for AIDS drugs and it is still cumbersome, 
it is still slow and that is to protect the recipients of the drugs. My patients' 
contention is that they will be dead in 18 months anyway from their AIDS -- those that 
have full-blown AIDS. And they -- if they want to take the drug and test it and don't 
care that their lives are shortened, then why does the federal government stand in 
the way? That is their contention. 
SENATOR MARKS: Thank you. 
CHAIRMAN HART: Could I ask on the -- one of the questions on the state's payment 
for AZT, your testimony was that they will pay for people who have AIDS; you think 
they will, I presume, will soon be ••• 
DR. FLYNN: We hope so, it would ••• 
CHAIRMAN HART: ••• issuing an administrative ruling that they will pay for people 
with ARC, that they will not pay for people who are HIV positive who do not, at this 
point, have ••• 
DR. FLYNN: That's my understanding at the present time, yes. We haven't tested 
that. We can't really afford to test it; we're testing it with just ARC right now. 
CHAIRMAN HART: I see. 
DR. FLYNN : See. Med center can't absorb that much. In conclusion then, the 
person with AIDS s uffers from -- and from HIV infection -- suffers from social ostra-
cism, including loss of job and insurance, from ill health that is progressive to 
full-blown AIDS; from psychological problems that involve knowing that eventually they 
will probably get AIDS and die of it; and the second psychological problem is they've 
been through it with someone else and they know what it's like and it is not something 
that they want to think about. 
Our resources are limited; volunteerism helps a great deal, it makes the quality 
of life of our pati ents much better, but as in San Francisco, volunteerism has a limit. 
People get burned out. And eventually it will fall to insurance and Medi-Cal and 
===.L-~=:.o.::e,_,n~t=--.:f..:u:::n=ds to rovide some of those services that volunteers are now 
providing. 
CHAIRMAN HART: Doctor, could 1 ask one final question, and I don't mean to appear 
ghoulish, but this thought has crossed my mind; could you describe how AIDS compares 
to other terminal illnesses, to a lung cancer or to other things that we all sort of 
have some abstract fear of, in terms of how the disease progresses. I sort of have this 
impression that AIDS is particularly debilitating and awful but is it really any more 
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awful than some of these other awful diseases that we, we dread? 
DR. FLYNN: You've made a very good point. One can compare it best, I think, to 
cancer; to an incurable cancer with a terminal illness time of about a year and a half. 
That would be things like lung cancer -- often kills quicker than that; disseminated 
cancer is metastatic cancers of the breasts and other organs -- take about a year and a 
half often to kill the individual. It's a similar course, as well. They lose weight, 
they become weak, they require treatment frequently, they're hospitalized frequently; 
so the cancer model's a very good one. 
Now, for cancer patients we've developed hospice, and we've developed fairly 
sophisticated hospice programs that rely on families, that rely on people having other 
people in the home. Our hospice, for instance, requires that there be an average 
of 1.7 care-givers in the home for the person who's going to enter hospice. We've been 
able to get some of our AIDS patients into hospice now, because they have that kind of 
support. But remember that many of our patients are gay men who have --whose families 
have severed their ties with them for one reason or another, usually out of prejudice 
and fear that their son is gay, as well as their lover has left because their lover 
can't stand to see them die of this disease that they're going to go through as well, 
and they're left alone. They don't have res .. mrces that can plug into hospice type 
programs and so we're again left with putting them into the hospital and various stop-
gap measures to try and take them through those last months. 
So there's the difference, I think. AIDS is feared and there is prejudice against 
it that doesn't occur as much with cancer. It used to; in the early part of this 
century, cancer was treated by the general public much as AIDS is today. People with 
cancer were shunned and ostracized, and that has changed. 
SENATOR MARKS: Let me add ••• 
CHAIRMAN HART: Senator Marks. 
SENATOR MARKS: ••• to this just one more question. What percentage of your pa-
tients, that you've estimated, are not gay people? 
DR. FLYNN: Probably 20-30% of my patients are not gay. I have IV drug users, 
many of whom have come home from New York City to be with their families as they get 
ill and die; many of them picked up the virus in New York City, which as you know, is 
the center of drug abuse for the United States, and many of our addicts have been in New 
----"YOrtt- crey-at sometlmeoetween 1979 and 1985 and picked up the virus there. I also 
have some people who received the virus through transfusion. Perhaps, of AIDS, perhaps 
3%, and of AIDS-related complex perhaps 5% of my patients are ••• 
SENATOR MARKS: So, it is correct that a certain percentage, maybe 20, 30% or 
maybe 3%, whatever figure you want, some percentage of this, of the people faced with 
this problem, are not gay. 
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DR. FLYNN: That's correct. And many of those currently are IV drug users; others 
·we estimate about 200 people in Sacramento who have the virus through transfusion. 
They're small, they're less than 10% of the total, but they will develop AIDS at the 
same rate ••• 
SENATOR MARKS: Thank you. 
DR. FLYNN: ••• in general. 
CHAIRMAN HART: Thank you very much, Doctor. 
DR. FLYNN: Thank you. 
CHAIRMAN HART: Our next witness is Dr. William Walker. Dr. Walker here? 
MS. KATHRYN DUKE: Yes. 
CHAIRMAN HART: Dr. Walker is the Medical Director for Contra Costa County ; is a 
member of the Executive Committee of the Health Officers Association of California; 
is a member of the Board of Directors of the California Conference on Local Health 
Officers and Staff Physician at Merrithew Memorial Hospital, which is Contra Costa's 
County Hospital. Senator Marks, you will be pleased to know he's a Graduate of Stanford 
University ••• 
SENATOR MARKS: Must be a very fine man. (laughter). 
CHAIRMAN HART: He's got a red tie on and. • • A Medical Degree from University 
of Colorado, he's Board Certified in Family Practice. Pleased to have you with us, Dr. 
Walker. We particulary wanted to get the views of a Health Director outside of San 
Francisco and Los Angeles, which are obviously the areas of greatest impact in Califor-
nia from whom we've heard on previous occasions; we appreciate your being here today. 
DR. WILLIAM W~LKER: Thank you, Senator. I'm going to try in a short period of 
time to give you some perspective on the impact of AIDS on a local Health Department, 
and what I -- Health Department from the medium-sized county, mainly a . population of 
about 700,000 in Contra Costa, with also a medium-sized burden of AIDS patients; what we 
are doing, how we are dealing with our current problem; it gives you some perspective of 
perhaps what the average county's experience is. 
We currently have 150 cases of AIDS in Contra Costa County. Of those, 83% are 
gay males , another 7% are IV drug users, another 4% are hemophiliacs, and 4% are trans-
fusion-related cases. We, at the present time, have been lucky from a county perspec-
tive in that more than half of those patients have been privately insured, and there-
fore, a substantial number are being cared for in the private community. We don't 
expect that to remain that way. We're seeing a beginning increase in IV drug abuse 
cases in our county and by the nature of our county facility, by the nature of our 
county responsibility, we expect more of those cases to be cared for in the county 
health system. 
Dr. Flynn has alluded to the financial problems that Sacramento County's facing; 
- 30 -
our problems are really no different. We are underfunded both by Medi-Cal and by the 
medically indigent adult program, and unless some alternative way can be found to 
finance the care of AIDS patients, our programs soon will be bankrupted by the burden 
that seems to be coming down the line. I told you we have 150 cases now; we antici-
pate in the area of 700 cases by 1991. We, at the present time, are dealing with an 
aging county facility, a county hospital that should've been replaced 20 years ago, that 
absolutely needs to be replaced now, and are going through the planning stages of 
looking at how much of that facility needs to be devoted to the care of AIDS patients . 
It's become a major planning issue for our county. 
We are also dealing with the issue of AZT funding; there has, as you know, been 
a one-time-only amount of money made available to the State of California from the 
federal government and Contra Costa has its share of that money. The problem is 
dealing with what will look to be only a one-time funding issue; we will be able to 
start patients on it, but not necessarily continue patients beyond the 1 year funding 
level. Again, we're talking about $10,000 per patient per year of AZT funding and if 
the county remains having to pick up the burden of that, that quickly rolls up the cash 
register for us. 
From the point of view of impact on Public Health Department, I would like to 
share with you what a medium-sized county has been able do with limited resources in the 
area of prevention and in the area of dealing with the community impact. We've had to 
pull together resources from throughout our system: from mental health division, the 
public health division, home health care from the Nursing Department; pull together our 
hospice resources, pull together physicians from any county hospital system, and then 
also involve community resources in our efforts; the AIDS Task Force, a number of 
private hospitals and private physicians who are carrying a major role in Contra Costa 
County. 
What we're looking at in terms of the focus of our efforts, is what's been alluded 
to today, and that is, the main weapon that we have is focused education. We ' re dealing 
with broad community-wide education in a number of forums throughout the county, educa-
ting interested groups, educating health care workers, educating peace officers, emer-
gency room responders. But in terms of preventing the actual transmission of the 
disease, the most effective agent we have is one-to-one counseling with identified 
~at~nr~. Now~nat means being abre-t:o- Iaentify the patients to begin with, and for the 
most part, that means allowing patients the confidence and freedom to come forth volun-
tarily to be tested, to be counseled, both before and after their testing, and then, 
hopefully to have an impact on the behaviors which will affect their knowledge in their 
progression either to AIDS or their ability to avoid it. We are approaching this in a 
number of ways. We are doing screening in our STD clinics on a voluntary basis, we are 
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also doing -- excuse me -- STD is 'sexually transmitted disease' clinics --we are doing 
blind testing, that is unlinked testing, in our STD clinics and finding about a 9% 
positivity rate of those patients who are positive for syphilis. That is 9% of the 
patients who have a positive blood test for syphilis are also positive for the HIV 
virus. 
CHAIRMAN HART: Let's back up on that, on the -- when -- you were saying that when 
people come to the STD clinic, they are voluntarily asked if 'they care to undergo an 
AIDS test? 
DR. WALKER: That's correct. An HIV test, pardon me. 
CHAIRMAN HART: But then in addition to that you ••• 
DR. WALKER: In addition to that we're taking the blood samples which we're drawing 
for VDRL's, for syphilis testing, and testing those for HIV positivity. Those are 
not linked to the patients names, but that gives us an understanding of what the percen~ 
tage of HIV positivity is in that particular subset of the population. 
CHAIRMAN HART: What percentage, well, when people come into the clinic, what 
percentage are willing to undergo the test? 
DR. WALKER: A majority of the people who are coming into the clinic are willing to 
undergo the test, given the confidentiality thac exists around that test at the present 
time. We are also continuing to do work with the Sheriff's Department in the jail, and 
we're doing voluntary screening in the jail at the present time, trying to get some idea 
of the problem as it presents in our health care facility within the jails, also within 
the wider jail population. 
CHAIRMAN HART: Is that voluntary testing? 
DR. WALKER: That's voluntary testing. 
CHAIRMAN HART: Of every jail inmate, or only those that you think are in a high-
risk category? 
DR. WALKER: That's voluntary testing of every jail inmate who chooses to be 
tested, and we also have an extensive education program going on in the jail advising 
inmates of what AIDS is all about, how it can be prevented. And we're finding as a 
result of that education program, many are wanting to find out their level of positivity 
while they are in the jail. 
CHAIRMAN HART: And what percentage are vqluntarily testing in your jail? 
--------- -----
DR. WALKER: The percentage is well over 60%, at the present time, who are stepping 
forward to have the test done. 
CHAIRMAN HART : And if someone tests positive, what happens then to that person? 
DR. WALKER: He's extensively counseled with regard to the risk of his disease, 
he is not physically isolated in the jail at the present time. The issue that one gets 
into in mandatory across-the-board screening in jails is that you have to decide what 
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you're going to do with the results. And if in fact you're going to take it upon 
yourself as an institution or as a county to separate the jail into two populations, 
positive and negative, then you have to assure that you're able to keep those two 
populations apart and you have to be assured that your testing mecha ism and repeated 
testing mechanism is good enough to make sure that those people are kept apart. We ••• 
CHAIRMAN HART: So, you don't keep them apart because --you don't have the facili-
ties to keep them apart or you don't think it's good public policy? 
DR. WALKER: We don't have the facilities, nor do we think it ' s good public policy 
at the present time. 
CHAIRMAN HART: Why do you think it's not good public policy if you, let's say, 
you did have the facilities, why would you think it would be bad public poli cy? 
DR. WALKER: If -- for one -- for the matter that I just alluded to -- I think that 
keeping people apart obligates us to assure that the people whom we've declared as 
negative are indeed negative. And that involves, because ·of the nature of HIV posi-
tivity, retesting over a period of time because the patient, for example, may come 
into the jail negative and convert after he's been tested since there's up to a 6 month 
lag period between infectivity of the virus and conversion to an HIV positivity. I 
think that that's a major problem even in and cf itself. And I think that the problem 
is better addressed by extensive education in the jail, by making inmates aware of what 
they can do to prevent not only being infected but also prevent passing on the virus to 
other inmates. 
CHAIRMAN HART: Are the people who work in the jail made aware of who is HIV posi-
tive, I presume that's -- would be a violation of state law unless the person agreed 
to that informa t i on being shared. 
DR. WALKER: That's right. That's up to the individual inmate to share that 
information. What we've done is extensively educate our peace officers with regard to 
precautions in handling or being -- having contact with body fluids of any inmates and 
those precautions really need to be instituted across-the-board. 
CHAIRMAN HART: Senator Marks. 
SENATOR MARKS : Let me say that I agree with the admonition of the Chairman that 
we shouldn't debate the Doolittle bills, we're not -- I'm not trying to do that here. 
But I do think it would be helpful to us, at least to have some indication from a 
-----m:elilcal s t andpoint , which you are, as to why the Health Officers were opposed to all of 
his bills. That would be helpful to us to know, from a medical standpoint, why it is 
that you were concerned with the bills because that would be helpful to us in determi-
ning where we should go. 
DR. WALKER: I won't address the bills specifically; I will address the general 
principles by which we evaluate all legislation, particularly as it comes to HIV test-
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ing. The primary reason for the testing is, at the present time, is focused education. 
We feel, and I think that our experience has been borne out in a number of studies, that 
any testing that requires mandatory testing will simply drive those people underground 
who need to be tested. 
Second, if the testing that ' s done is not either anonymous or strictly confiden-
tial with antidiscrimination policies in place, people will not come forward for that 
either. So, we evaluate testing legislation on t hose two principles to begin with. We 
further look at testing with regard to what it will do from a public health perspective. 
Now, for example, premarital testing; although premarital testing can be done, we've 
done it with syphilis, we've required premarital testing in a mandatory way. In fact, 
the most recent study that's been done shows that premarital testing across the nation 
would pick up .1 of 1% of HIV positive patients at a cost of well over 100 million 
dollars. That same effort would produce about 200 patients who are infected and yet have 
been told they're negative; it would produce another 350 patients who are negative and 
yet have been told they're positive. And from a point of view of public health, that 
doesn't make any sense. 
What does make sense is what we've done as a Legislature and as a State, and that 
is make HIV testing voluntary at the time of getting married so that this specific issue 
is raised for married couples; that focused education can occur; that if counseling 
can occur a few questions can be raised, and for those patients who consider themselves 
at risk, then voluntary confidential testing can be done. That makes sense. We, 
across-the-board as Health Officers, recommend and encourage widespread voluntary 
testing for anyone in the population. Anyone who feels they're at any risk whatsoever 
should be allowed to come forth, be tested, be counseled. 
We're opposed to anything which will in any way make it difficult for people 
to come forth voluntarily or make them afraid to come forth voluntarily. And those 
are the general principles by which we're evaluating all legislation at the present time 
with regard to testing. 
SENATOR MARKS : Thank you. 
DR. WALKER: I'd further like to say that there have been some very good pieces 
of l egislation come forth with regard to education and unfortunately not many of the 
pieces have made it through the entire process and some of them have made it with a 
veto. 
I 1 d like to share with you that, at a local level, we've been able to do some 
things on our own working at one-on-one with the local school districts, and we've 
developed a model curriculum in Contra Costa County and with the cooperation of the 
school administrat i on, the PTA's, the teachers, that involve very explicit education for 
junior high and high school students. We've developed a curriculum which will be used 
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throughout the county and we ' re going one by one to all the school districts to get 
approval of that. 
I think that if the state could look to what is the most important thing to be 
done, it would be to require counties to come up with a plan for AIDS. Namely, require 
county health departments which really are the arms of the State Legislature and the 
State Administration -- we're the troops in the field; require us to come up with a 
plan, put some requirements on what that plan ought to entail, and then provide us with 
the resources of how to carry out that plan. 
I have before me a 49-page document which is the 3 year plan for Contra Costa 
County which is in its final draft stage; it will be going to our Board of Supervisors 
in the next few weeks. That is an ambitious plan which will, I think, effectively deal 
with AIDS in Contra Costa over the next several years. It will only happen if we have 
the resources to do it. It will only happen if we get the resources in a way that can 
be used to meet the needs of our county. Now, the most effective way for the state to 
pass resources onto us, truthfully, is in the form of block grants with minimal require-
ments in terms of reporting back to the state. Some of the educati.on money that we have 
received has been helpful, but frankly, some of the hoops that we've had to jump through 
to use that money, namely getting all of our pieces of educational material approved; 
having, for example, the test kits -- were leaving the jail to go back for approval by 
the state; in my opinion, simply, roadblocks to doing an effective program. If you 
could simply trust your local health departments enough to give them the credit for 
having insight into what's going on in their own counties, give us the money to do 
the job; I think we can do the job very effectively for you. 
Now, that doesn't address where you're going to get the money. Dr. Flynn has 
talked about the problems of money on the acute care side. Public health is no dif-
ferent. The resources are going to have to come ultimately, I think, from the federal 
government. We are, in Contra Costa, looking at a proposal now which we'll be taking to 
the Bay Area Health Directors at our monthly meeting and ultimately to our Board of 
Supervisors for proposed legislation to begin to fund AIDS in a pattern similar to the 
Short-Doyle program. 
Short-Doyle, in addressing the mental health needs of the state, in many ways has 
some of the same problems facing it that the AIDS program does. That is, it's a problem 
that imp~c~s-the en~rre-communitj;-rt's a pro lem tat the community cannot handle on 
its own with its own resources; it's a problem that could be best addressed by Advisory 
Boards from the local community; it's a problem that the state could, in fact, lay out a 
general plan for and require the county to come up with a plan, an AIDS plan just 
like we've come up with a Short-Doyle Plan; it's a problem where the county pays part 
of the share, the state pays part of the share, and ultimately, hopefully, the federal 
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government could pay part of the share. 
This is a completely independent funding for AIDS outside of the context of nor-
mal public health funding, outside of the context of normal acute care funding. But 
it's going to take something innovative to get it off the ground for us to begin to 
have the resources in place to do what we need to do. So I'd ask you, as you develop 
legislation, to look at broad methods of being able to pass on money to counties in 
the form of block grants. I would ask you that when you come up with specific proposals 
with regard to policy on AIDS, with regard to testing on AIDS, that you view it in 
the context of the broad problem; that you view it in the context of the principles 
you need to look at in evaluating testing proposals, and that you consult with your 
professional staffs, both at the state level and at the local level, with regard to 
professional public health input in developing new legislation. Thank you. 
CHAIRMAN HART: Questions? 
I'd like to ask 2 questions if I may. You mentioned syphilis and marriage require-
ment. Could you comment on the -- I mean, oftentimes here we ought to deal with AIDS 
like we deal with other diseases like syphilis. To what extent, from your standpoint, 
is that an appropriate analogy and, if not, why not? Why does it break down? 
DR. WALKER: I disagree with the argument that AIDS is simply another sexually 
transmitted disease. It's much more than that; it's much different from any other 
sexually transmitted disease we've ever had. For the first reason being it's not 
treatable at the present time, and that the programs we've had in place for STD's in 
the past including screening, including contact follow-up, have been with the promise of 
being able to offer treatment for those people who are found, and also there have not 
been big issues of discrimination or nondiscrimination with regard to those diagnoses; 
that's number one. Number two, AIDS, from a national viewpoint, has tremendous social 
and political overtones to it that are much different from any infectious disease we've 
ever faced before; particularly much different from any STD. So I think that using the 
STD model to deal with AIDS is wrong. 
CHAIRMAN HART: Okay. The other question that I wanted to ask is could you comment 
on contact tracing? Is your county involved in that at all, and can you help us under-
stand that a little bit better; how it works or should work or· what the pitfalls are? 
DR. WALKER: We're doing limited contact tracing in our county at the present 
time, particularly following up contacts of transfusion-related AIDS, hemophiliac-rela-
ted AIDS as well as IV drug use-related AIDS. The reason that we have done less contact 
tracing in the gay population is that it's our opinion that efforts are best spent in 
that population on individual focused education and addressing the population as a 
whole. We think that our education efforts in the gay community have been good and 
primarily that has to do with the organization that exists within the gay community. 
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We find that the other problem in contact tracing is simply the incubation period of 
this disease. We're talking about a disease that has an incubation period on the 
average of 5 years. We're talking about contact tracing into the distant past which 
isn't always do-able, it's difficult, it's expensive and in our view, the resources that 
we would need to put into that aren't warranted given the potential outcome. 
CHAIRMAN HART: So given the 5 year period and given the fact that you're not 
doing much of it in the gay community ' cause you don't think it's the most effective 
way, does that mean t hat you ' re not doing contact tracing? 
DR. WALKER: No, as I sai d, we ' re doing it in other focused areas. We're doing 
it in heterosexual contacts of people who would be unaware that they were at risk. 
I think, there's one thing that can be said, at the present time, across-the-board I 
don't think there's a gay person alive who doesn't think he or shouldn't know that 
he's at risk and that he should come forth for testing and be tested. That can't be 
said of people who have been anonymously in contact with an HIV positive person and 
those are the people, I think, who need to be sought out in the population since they ' re 
out there not knowing they've come in contact, and whe~e contact follow-up is appropriate 
on a one-on-one basis. 
SENATOR DOOLITTLE: I have a question on thA~. 
CHAIRMAN HART: Senator Marks and then Senator Doolittle. 
SENATOR MARKS: I don't quite know how to word this, but . there are some statements 
that 've been made by a number of people relating to the manner in which you can get 
AIDS. Can you get AIDS by shaking hands with somebody? 
DR. WALKER: No. I think that the overwhel~ng evidence, I think you can say 
for certain, is that AIDS (void in tape) get it from the air, you can't get it from an 
AIDS pat j ent sneezing in your presence, you can't get it from shaking hands of an AIDS 
patient, and as Dr. Francis said, there have been now some 9 cases out of 42,000 
cases where there's been transmission from what's been less than intimate contact; those 
have been IV -- correction -- those have been needle puncture cases in health care 
workers, and a few cases of what's called 'splash contact' where the body fluid or blood 
of an AIDS patient has been 'splashed' on either an open sore or mucous membrane of a 
health care worker. Those cases have occurred; more of those few cases will continue to 
occur. Health care workers are at risk, but I think that the overwhelming sense of what 
----We-!..;r;e--loeking at is it's a very, very small number of cases .give·n the hundreds of 
thousands of health care workers that have been in contact with AIDS patients. 
SENATOR MARKS: Can you get AIDS from mosquitos? 
DR. WALKER: No . 
SENATOR MARKS: Can you get AIDS from sitting on a toilet? 
DR. WALKER: No, you can't. 
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SENATOR MARKS: Trying to think of some of the other excuses that have been spread 
relating to AIDS. Do you know any other examples of ways in which you cannot get 
AIDS? 
DR. WALKER: I can only tell you the ways you can get AIDS, and everything else ••• 
SENATOR MARKS: All right, why don't you tell us that. 
DR. WALKER: Okay. The ways you can get AIDS are, number one, having intimate 
sexual contact with a patient who is HIV positive. There are risk behaviors of that 
intimate contact, the biggest risk behavior is anal intercourse; it's much more diffi-
cult to transmit it from a female to male but it does occur, but very rarely; it --
that's the first way you can get it, therefore, is sexual contact. 
The second way you can get it is by IV exposure; IV drug exposure from a conta-
minated needle, for example. The sharing of a needle with an AIDS patient exposes you 
to the virus because the virus gets directly into your bloodstream when you inject the 
drug. The same transmission, note, applies to people who've received the virus through 
transfusions; through a contaminated blood source. That includes hemophiliacs, it 
includes people who have had transfusions during surgery. 
Those are the -- as I alluded to, there have been a few cases of transmission of 
splash contact to open sores or to mucous membranes, and those are the only ways that 
you can get AIDS. 
SENATOR MARKS: Thank you. 
CHAIRMAN HART: Senator Doolittle. 
SENATOR DOOLITTLE: Do you accept the CDC's report that some 88% of HIV infected 
people are unaware of their infection? 
DR. WALKER: Yes, there is a -- the number that's being used, is that there is a 
perhaps 10-1 ratio of HIV positive people in the population versus those that we have 
identif ied. 
SENATOR DOOLITTLE: Of 10-1, okay. So, do you feel that -- I guess you don't 
feel, as the health officers have taken that position pretty clearly but, don't you 
think we need to do something more in order to call to the attention of those people who 
are infected, that they have a problem? I mean isn't that when people really become 
receptive to l istening to the educational message? 
DR. WALKER: Absolutely. And the onl ive that 
education to them is if they come forth and get tested. 
SENATOR DOOLITTLE: Well, since this tends to be -- I mean we didn't go into this 
before, but, a lot of people tend to assume that this is something that always happens 
to the other guy. And isn't that a psychology in serious diseases? 
DR. WALKER: Yes, it is. I think that the message is beginning to get out there 
though. I think the evidence is somewhat in our alternative test sites in our county, 
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where we've done some 5,000 tests in the last couple of years. That the percentage of 
positivity of those tests are going down. So that initially we had people who were 
coming in who were quite at risk coming forth to get tested. As we go along, the 
percentage of positivity is decreasing and that's because more people who might have 
casual contact in the past, 'scuse me, might have had intimate contact with a poten-
tially HIV positive person, are coming forth to be tested; their risk has not been 
great. We also have a lot of worried well out there who are concerned that any symptoms 
mean AIDS. So as they come forth to get tested and find that they're negative, that 
allows us to do a couple things. Number one, it allows us to counsel them about how 
never to get positive. And it also has allowed us to talk to them in an anonymous 
way, where they can enjoy complete confidence; they can come forth, find out their 
status, be counseled, and go away with valuable information. My feeling is if we don't 
have that kind of test site available, and if we try to do the tests in a mandatory 
way, we'll simply drive people away from being tested -- drive them away from coming 
forth for that kind of education that they need. 
SENATOR DOOLITTLE: What about adding the possibility of having more widespread 
routine screening in addition to what is now going on? 
DR. WALKER: I don't like the word routine. It's too open to interpretation. 
I think that testing is either anonymous, confidential, or there's open access to 
anyone. There's no such thing as routine. 
SENATOR DOOLITTLE: But by routine I mean applying the same standards to that 
blood test as are applied to the other blood tests. 
DR. WALKER: I disagree with using the test that way. Primarily because with 
other blood tests, for example, if I want to know whether I'm positive for rheumatoid 
factor, that's not a confidential test; it'll be 'in my medical record, it'll be open to 
any one of a number of parties who want to request my medical record for insurance 
purposes or whatever. But there's one thing that's true, and that is -- will not be 
discriminated against because I have a positive rheumatoid factor. 
SENATOR DOOLITTLE: Well ••• 
DR. WALKER: That's not true for the HIV virus and until we have the antidiscrimi-
nation policies in place, one cannot think of, quote, routine testing. 
DR. DOOLITTLE: So until we have such policies in place, you would oppose a propo-
sal that would-allow a physician to disclose to his nurse or to other medical personnel 
assisting that patient that that patient test positive? 
DR. WALKER: No, I think we're very close to being able to do that. In fact, 
we almost did it, I think, with AB 67. 
SENATOR DOOLITTLE: Well, yeah, but I'm saying -- I mean your price for that 
is antidiscrimination language? 
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DR. WALKER: Yes. 
SENATOR DOOLITTLE: In the absence of antidiscrimination language you as a health 
officer and a physician, would oppose a line of disclosure of such information to 
the other health personnel. 
DR. WALKER: I can tell you, in real ity , the people who are having hands-on contact 
with patients in the hospital now; we're talki ng about the nurses, we're talking about 
the treating physicians; by and large ~now t hat patient's antibody status if, in fact, 
a test has been done. The problem we get into there is whether every patient that 
enters a hospital should be tested, and again, I would not want to approach that until 
we had in place protections against what , I fear, is the absolute worst discrimination 
which can occur and which, I think, we're beginning to see. And I have some concerns 
about members of my own profession. I'm seeing physicians come forth asking for testing 
with the implication that, with a positive test, they'll refuse to treat the patient. 
Now right now, there's no piece of legislation; there's no law that requires a physician 
or a hospital to treat a patient. He could be discriminated against. And until we have 
legislation in place which says you cannot discriminate against an AIDS patient because 
of his antibody status or anything else, I would oppose the kind of screening that's 
being proposed for hospitalized patients. 
SENATOR DOOLITTLE: Well, if we had such antidiscrimination language, would you 
be concerned that t hat could require a hospital to maintain on its staff a surgeon who 
tests positive, or a restaurant that maintain on its staff a person who tests positive, 
I mean, would that concern you? 
DR. WALKER: No , it wouldn't concern me. 
SENATOR DOOLITTLE: Well, I would suggest it would concern me and a number of 
other people in the state who are very concerned about the transmission of AIDS in those 
cases to other peop e. And that ••• 
DR. WALKER: There's never been a restaurant-transmitted case in the history of 
AIDS. 
SENATOR DOOLITTLE: Well, I mean, we know so little about, really, these cases; we 
know there ' s a good deal of evidence on the sexual transmission; I think the blood 
spilled on t he chapped skin is a very, very serious example about AIDS and shows the 
potential for its transmissibility; the fact that there've only been a few examples, I 
mea n how do you even document or prove something like that. It's going to be difficult 
:l.n the fir s t place but the very fact th<lt: w':, do have few documented cases suggests that 
w·~ r:·.~ ed to take a clo~.E: look at t!us. c.~p~ainly, ti1e people i 1 rhe health care profes-
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surgery, and so their level of exposure is much higher than the typical person's in our 
society and, you know, do they treat every patient as if he has AIDS? This man happens 
to feel if they do that, it means wearing extra clothing, so it makes them hotter as 
they're going through the surgeries; he feels that makes him less effective as a surgeon 
in terms of being able to do all the concentration and application of skill and then if 
he has to double-glove , then all of that he feels there's less sensitivity. So there 
are some real trade-offs and, you know, I just think the health officers need to take a 
more critical look at this issue than blatantly or blanketly support the antidiscri-
mination provision without recognizing that there may need to be some exceptions, some 
adjustments as we go along the way. 'Cause there's some real trade-offs, I think, that 
we're making and we need to recognize we're making them as we go down this path. 
DR. WALKER: I think we came very close to putting a bill across which we supported 
which would have provided for the confidential testing in the hospital; it would've 
provided for the passing out of information to the health care team. Unfortunately, 
in the final hours of legislation, it didn't make it. Let's hope that this time around 
it does make it • 
SENATOR DOOLITTLE: Well, I don't hope that it does, I mean, I was the key party, I 
think, that made sure it didn't make it in the Senate. And the reason I did that was 
because it had this broad antidiscrimination language that didn't allow for any excep-
tions. For one thing, even if you look at it -- if we get beyond the actual medical 
issues -- hospitals are having a hard enough time as it is. What do you suppose happens 
if word leaks out the hospital's keeping on it's staff a doctor who has AIDS? 
SENATOR MARKS: Chairman, can I just say something? 
CHAIRMAN HART : Senator Marks. 
SENATOR MARKS: With all due respect to Senator Doolittle, and I have a lot of 
respect for him although I don't agree with him on this, he's not a doctor, he's not a 
health officer, he's not a nurse. The doctors of California, who I presume number 
among their people, Republicans and Democrats and Independents, or the health officers 
or the nurses have all (void in tape) who is opposed to these principles, but I cannot 
conceive of how we should pay attention -- he 1 s a loyal like I am -- how we, on a 
medical matter, a matter involving the health of people, we should pay attention to his 
concerns -- obviously, we're all concerned, but will we pay attention to his v_i_e_w_s __ _ 
rel at i ng to the health aspects of this problem. I cannot conceiv.e why we should not pay 
attention on a medical matter, to the medical societies, to the nurses, the health 
officers -- those are people who have an independent judgement of this problem. 
SENATOR DOOLITTLE: Well, Mr. Chairman, if I might just comment on that. 
CHAIRMAN HART: Briefly. 
SENATOR DOOLITTLE: It is not the doctors or the nurses that make social policy in 
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this state, it is the Legislature and we look to the doctors and the nurses on medical 
issues to advise us. There's a significant division within the medical community. It's 
more significant than it's ever been with doctors coming forward and saying, "Hey, we 
need some protection; we're concerned that we have a more balanced approach," so I hope 
that you wouldn't create the impression that there's a monolithic attitude amongst the 
health professions 'cause there certainly is not. 
SENATOR MARKS: No, I don't think it's a monolithic attitude; I'm sure that you'll 
be able to find people who agree with you here and there, but I'm saying as an organiza-
tion; they are an organization which meets, I believe, democratically, determine 
its position on matters, and they are not people who are particularly involved in 
politics per se; they're involved in the medical or health matters involving the State 
of California and they come up forward with presentations, and they have, universally as 
a group, opposed your bills. 
SENATOR DOOLITTLE: Well, I would just observe, there's more politics in this AIDS 
issue at every level than in any other issue we can probably think of today, both within 
these organizations and without. 
CHAIRMAN HART: Okay, Dr. Walker, let me -- I'd like to ask one final question if 
I could, of your testimony as it relates to doctor's ability to reject an AIDS patient; 
you said there are no laws in California that preclude ••• 
DR. WALKER: That's right. 
CHAIRMAN HART: I was under the impression that there were BMQA rules that do 
apply and that if a doctor did refuse to see an AIDS patient, that they would be subject 
to licensure disciplinary actions, is that not the case? 
DR . WALKER: I'm not aware of any BMQA rules. As you know, we had to face it 
in terms of emergency room treatment and in terms of patients being turned away from 
emergency rooms , and in fact, had to invoke anti-dumping legislation in that area, which 
imposed penalt i es on physicians who were refusing to treat. Those same kinds of issues, 
I think, are -- involve AIDS cases at the present time. The only thing that would 
govern a doctor ' s performance in the hospital is an individual medical staff ruling; 
that he was required to treat all patients who came in the front door. If the hospital 
and medical staff took on that ruling as a policy and a matter of being a member of the 
medical staff , then that would be in place. I don't believe that BMQA enters into 
that. 
SENATOR DOOLITTLE: Okay, thank you very much. 
CHAIRMAN HART: Our last witness this morning is Dr. Alex Kelter, representing 
the State Department of Health; he's the acting Deputy Director Public Health for 
the Department. Dr. Kelter, welcome. 
DR. ALEX KELTER: Good morning, Mr. Chairman. There's an obvious advantage to 
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appearing late in an agenda like this, and that is that many of the important points 
have already been made, and they certainly have been. 
The disadvantage of appearing late is that the important points have already been 
made, and they really have been. (laughter) So, what I would like to try and do is just 
briefly, use a couple of my prepared remarks to summarize some of the issues that have 
already been alluded to, and then cover a couple of items that you've requested, namely 
the history of AIDS funding, the organization, and the department, and those type 
things. 
Mr. Chairman, members of the Committee, thank you for the opportunity to testify 
today. Dr. Kizer regrets not being able to be here personally; he has had a long-stand-
ing commitment that would not allow him to be here, but he did ask me to specifically 
apologize for that. 
In the overall scheme of medical science, it's really phenomenal that we have 
progressed as quickly as we have, from the first recognition of a brand new disease of 
the human species to the identification of a previously unknown and unsuspected virus 
which causes it in a mere 4 years. Furthermore, it is possible that the first human 
trials of prototype vaccines and additional treatments, that is, additional to AZT, 
would be started in the next year or so. Another rather phenomenal development. 
Yet, with all of this remarkable advance in human virology and immunology and 
therapy, the fact remains that everything we need to know to prevent virus transmission 
was known with virtual certainty by the end of 1982; before the virus itself was even 
discovered. All the scientific advances that have been in the ensuing months and years 
have confirmed and strengthened what we knew then. 
AIDS, HIV infection, is a disease transmitted by sex and blood. The way to avoid 
transmitting it and acquiring it, is to avoid the exchange of specific body fluids, 
semen and blood, with another person. To the extent that it is possible to know this, 
all cases of infection off-rank AIDS have been acquired either through direct sexual 
contact with an infected person or through direct blood to ~lood exposure to an infected 
person's blood, and this would also include the maternal and child exchange of virus 
during gestation and delivery. 
The challenges before us now are not materially different from other challenges we 
face; we know what must be done, but we're struggling over the best wa s in which to do 
it. Some might question our collective commitment to prevent AIDS because they do not 
see their favorite methods being adopted and applied universally. We know enough about 
preventing AIDS, and we have for some time. What we're continuing to pursue is the mix 
of messages and methods that will make what we know meaningful to the people whose 
behavior will directly determine the level of AIDS prevention that we ultimately achieve 
in our society. 
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The current mixture that we and others administer in the Department of Health 
Services, at the national level and certainly at the local level, includes a number of 
different approaches. At the state level, we take responsibility primarily in the state 
where the compilation of statistics and the support of epidemiological and statistical 
research; we support special studies and we keep a finger o·n the pulse of AIDS incidence 
and prevalence and HIV infection in California; a level of activity which is sometimes 
called monitoring, if you will. 
A very important element of that project and that program is the support of alter-
native testing sites. As you know, alternative testing sites have been available since 
the day the test was approved by the Food and Drug Administration in 1985. And at the 
current level, we are testing in excess of 11,000 people per month in alternative test 
sites around California. 
In the area of medical care, we are supporting a number of pilot projects whose 
goals are several. Most importantly, they are to experiment wi.th the providing of care 
to people with AIDS, and to some extent with ARC. And to develop reliable information 
about how much this care .costs and how much, perhaps, can be saved by a more judicious 
mix of more cost-effective methods of treatment; and along these lines, we are applying 
to the federal government for a waiver from certain Medi-Caid rules, which would allow 
us to pay for some non-hospital care in the Medi-Cal program which is now not permitted. 
Of course, I couldn't describe the State AIDS program without focusing on education 
and prevention. In the current year, almost 7 million dollars are being spent statewide 
to support specific education and prevention programs in communities and counties all 
over the state. In addition, there are a couple of elements of research support that we 
conduct through public health in addition to those that come to the University of 
California which involve a program to make funds available for testing of AIDS vaccines 
once they become licensed and approved by the FDA, and of course, the recently enacted 
AB 1952/SB 618 program to allow the state to award investigational new drug approvals to 
those who wish to test new drugs within California and not extend beyond the borders of 
California. So, you can see that the Department and state as a whole is deeply in-
volved , and has been from the beginning, in a wide range of activities dealing with 
the identification of treatment and prevention of AIDS. I'll take a moment to review 
the history of funding of those programs because it's rather impressive. Going back to 
the 198-••• 
CHAIRMAN HART: Doctor, let me just -- one of the things that I wanted to ask, and 
I'm sorry Dr. Kizer isn't here; I have a general concern that the Department is not very 
visible on AIDS issues. I don't see the Department out there sort of (void in tape) 
education that the vaccine legislation that you made reference to, I believe, was an 
idea that came from the Attorney General, not from the Department of Health Services. I 
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mean, I sort of have a general impression of the Department of -- kind of gathering 
statistical data, which is very valuable, but it's fairly -- I mean, let's be blunt 
about it, it's a noncontroversial area. When you get involved in the controversies, I 
don't see much in the way of the Department of Health Services visibility one way or the 
other. 
DR. KELTER: Well, I don't know, Senator, what I can say that would -- that might 
change your perspective, I think ••• 
CHAIRMAN HART: I guess I raised it in the context of the vaccine. You were 
talking about the Department of Health's role, and I thought it was really the Attorney 
General who was responsible for that. 
DR. KELTER: The Department has had the authority and has had the willingness to 
entertain that kind of activity for some time, but, I really have to view it as a 
program that's jointly been agreed to and is going to be carried out by the Legislature 
and the Administration. Certainly, the Governor had the opportunity to veto the mea-
sure and didn't, and the Department is forcefully and speedily beginning to carry out 
that program. So, I guess all I can really say is, that this has been a joint agreement 
between the Legislature and the Administration, that this activity would be undertaken, 
and it is being undertaken. 
As far as our visibility is concerned ••• 
CHAIRMAN HART: Senator Marks. 
SENATOR MARKS : I'd just like to ask one question -- I'm not trying to make an 
issue, but just to follow along with what Senator Hart asked about; much of the legis-
lation that has been passed, the Legislature calls for additional funds relating to 
AIDS. Much of that has been vetoed by the Governor. Has your Department recommended 
the vetoes? 
DR. KELTER: Without having a list in front of me, well ••• 
SENATOR MARKS: I don't have a list either. 
DR. KELTER: Well, the Department's advice to the Governor has often been, I'm 
sure, instrumental in the Governor's deciding which position he takes, but he alone 
makes the final decisions about what bills will be signed and vetoed. 
SENATOR MARKS: But do you recall that the Department has recommended vetoes of 
certain appropriations the Legislature has approved? 
DR. KELTER: Senator, quite candidly, I don't recall which recommendations of the 
Department's were the ones the Governor finally accepted and which were not. 
SENATOR MARKS: It'd be interesting to have you, sort of, submit to us sometime, 
a list of those bills that you've recommended disapproval. 
DR. KELTER: Well, with all due respect, I think that's a request you'd have to 
make of the Governor's office, not of the Department. 
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SENATOR MARKS: Can I make it of you? 
DR. KELTER: Again, with all due respect, Senator, it's the Governor who makes the 
final decisions about ••• 
SENATOR MARKS: I understand that, but each Department makes recommendations. 
Are you telling me that the information relating to its recommendations -- I thought --
I understand the Governor makes a decision, but its recommendations are confidential? 
Recommendations? 
DR. KELTER: My understanding is that they are privileged communications between 
the Department and the Governor. 
SENATOR MARKS: Well, they shouldn't be. 
DR. KELTER: Reviewing the pattern of funding over the years, going back to the 
1983-84 fiscal year, the state's allocation to overall AIDS programs was about 3.4 
million dollars. The net effect of subsequent decisions over subsequent budget years 
has been to double t hose expenditures virtually every year. And while this did not take 
place between ' 83-4 and '84-5, the subsequent change was a quadrupl ing so the net 
effect was (void in tape) and from '86-87 to the current year '8 7-8, there was a doub-
ling in the overall state AIDS budget to the tune, now, of 63 million dollars in the 
current year. Of that, the Department receives about 2/3 of it, or 46 million dollars; 
University of California receives about 10 million, and the rest is distributed among 
other departments including Mental Health, Alcohol, Drug Abuse, Corrections for the 
total funding of 63 million in the current year. This is, far and away, a pace not 
exceeded by any other state in the United States, even the states that have more cases 
than us , mainly New York state, and is certainly not exceeded by the federal experience 
in AIDS funding. 
What we should look forward to in the future has already been well described by 
previous witnesses and I don't want to belabor those points; they were well made by Dr. 
Francis, Dr. Flynn and Dr. Walker. There are hundreds of thousands of people infected 
in California; they will require medical care, they will require compassionate care, 
both from medical and health professionals and from all of us in California society. 
CHAIRMAN HART: Dr. Kelter, can you -- in one of the statistics that's thrown 
around is that at a minimum, 300,000 people in California have the HIV virus and upwards 
of 50% or more of those people will ultimately get AIDS and die. We're talking 150,000 
deaths, minimum for over the next (void in tape) people will actually get the disease. 
Are those accurate figures by your Department or personnel. 
DR. KELTER: Yes, we agree with those estimates; they come from the Centers for 
Disease Control in Atlanta, but they're based on data that we and other states and 
counties and cities collect by programs like the Alternative Test Sites, by confiden-
tial testing in sexually transmitted disease clinics, and drug abuse clinics, and the 
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level of testing that we will see in our cities and counties all over the country is 
going to increase, and quite appropriately so, as the need for more seroprevalence data 
becomes (void in tape) but also for care. 
CHAIRMAN HART: Is that $300,000 -- 300,000 -- (void in tape) 
DR. KELTER: As I recall the range of estimate, it was from 1-500,000 and most tend 
to focus on the middle of that range as being the most accurate; 300,000 is the middle 
of the range. Some of the estimates were based on assumptions that our rate of infec-
tion, for example, in the IV drug using community, would follow the pattern that was 
seen in New York, New Jersey, and Florida. It's still too soon to tell whether or not 
we are repeating that pattern; there are some reasons to think at this point, we're not 
seeing as quick a rise in infection rates in the IV drug using population, but it's too 
soon to say that with any confidence. If we're slower than the east coast in that 
community, we might be slower in the overall estimate. And the estimate also was made 
for the year 1991, I believe. 
CHAIRMAN HART: Course, there was a story in the New York Times last week that the 
AIDS IV drug cases in New York was badly underestimated; that it seems, now, to be much, 
much greater than was originally anticipated. 
DR. KELTER: I understand, and we are work~ng very hard, both as a department and 
jointly with the Department of Alcohol and Drug and with county health departments and 
county drug abuse clinics, to greatly expand our knowledge about the infection rate in 
drug abuse clinics and in drug abusers. At this point, we are on the verge of producing 
the results of an important seroprevalence study that we conducted with counties in the 
spring, and I look forward to much more in the way of investigations into the infection 
rate in those sub-populations. 
I might also pick up one loose end that was left regarding the provision of medical 
care by medical and health professionals. Every year in the United States there are 
approximately 300 deaths from occupationally acquired hepatitis B infections among 
health care professionals. To this point, there has not been one AIDS death among 
health care professionals from an occupationally acquired infection. So, if health care 
professionals are concerned about acquiring infections that may kill them, at this 
point, their great concern should be with hepatitis B and not from HIV as far as risk is 
concerned. Both ' those diseases are transmitted largely in the same ways, in fact, the 
oDifi!rvatTon that they're transmitted the same way is what led virologists to be able to 
find the human immunodeficiency virus as fast as they did. The epidemiologists told 
them that this was transmitted the way that hepatitis B is, you should go look for a 
retrovirus transmitted the way hepatitis B is, and they found it. So hepatitis B, at 
least on a statistical basis and on a risk basis, is a much more important cause 
of death among health profes!ilionals who acquire their infections occupationally than 
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HIV is. With that, I will conclude my prepared remarks. 
CHAIRMAN HART: Could I ask, from the Department's standpoint, having been in this 
battle now for at least a couple of years or longer, what is the most critical thing 
that we ought to be doing now -- I mean, there are a whole series of issues that we've 
heard about; from the Department's standpoint, at this point in the battle, what i s the 
most strategic point that the State of California and Department's advice to the Legis-
lature might be in terms of where we need to be focusing our attention, our resources --
is there a -- in other words, is there a game plan that the Department has to give 
us advice on where we ought to be going at this point in time. 
DR. KELTER: I think the most sensitive issue at this crossroads in AIDS preven-
tion, is the delicate balance between a continued positive relationship between the 
community and government, on the one hand, and yet our ability to see more and more 
people tested, more and more people counseled, more and more people educated about how 
they can prevent infection for themselves, or if they're already infected, how they can 
prevent transmitting it, and in a sense. that sensitive issue is dealt with by the 
exchanges between Senator Marks and Senator Doolittle earlier this morning. 
Clearly. we have to maintain an open relationship with those portions of our 
population who are more infected; drug use community. gay community, people who exchange 
blood and sexual contact with people who engage in those behaviors; we must maintain a 
relationship of positivity, of trust, and of openness with them or we will lose our 
ability to compound our successes; successes that we've seen in the homosexual commu-
nity. 
Among gays, not only is the new aero incidence or the new conversion rate of HIV 
positivity down , dramatically down, the rate of gonorrhea is down, the rate of syphilis 
is down; the homosexuals in California have gotten the message that certain behaviors 
are risky. and the avoidance of those behaviors reduces your risk, virtually to zero. 
We have to maintain the ability to get the message out to the people who need to hear 
it and who need to learn it without keeping them at arms-length. And yet. at the 
same time, encourage testing • encourage confidential testing, which can be placed 
in the context of the medical care for that specific individual. Yes, we test 10. 11, 
12, 13,000 people a month in Alternative Test Sites, and yes, it allows us to teach 
people the risk factors for infection when we see them at the sites. And yes, those 
individuals can. if they choose to, make their infection status known to their health 
care provider. 
But I think everyone would be happier; I think the patients would be happier, I 
think the doctors and health professionals would be happier; I think we'd all be 
happier if such testing and such education were done directly in the context of day-to-
day medical care between a person and his or her physician and health professional. 
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And I think anything we can do to move testing and education and prevention into the 
mainstream of day-to-day health care will improve our ability to get the word out and to 
prevent additional cases of infection. 
So on the one hand, we want people to be tested, we want people to be educated, we 
want to maintain a positive relationship with them; we want to encourage more testing 
without introducing the idea that the price you pay for being tested is the possibility 
that you' 11 have a social or combined social and medical calamity in your life. We 
don't have a reward to offer people for testing. Syphilis and gonorrhea and chlamydia 
and all sorts of infectious diseases; we have a reward to offer people to be tested. 
And that is, we can treat them and cure them. Until we have a reward like that for HIV 
infection, we have to offer substitute rewards which are less potent, and at this point, 
the knowledge that your test is going to be personal between you and only people that 
you authorize, seems to be a factor which has brought thousands and thousands of people 
to testing who otherwise might not have been tested so far. 
CHAIRMAN HART: Two other questions. I was impressed by the hearing that Senator 
Seymour had last week in San Francisco where the thrust of the testimony was that 
transmission to the heterosexual community is largely going to come through the IV drug 
using community. And yet -- and I know that, I guess , from the budget, you know we're 
doing more than other states, but the point was that we are today where New York was 5 
years ago and New York didn't know where it was 5 years ago. And what we heard in the 
testimony was that we are -- if somebody comes in who's a heroin addict, possibly using 
dirty needles, and they come in and ask for treatment to get on Methadone or to go into 
some kind of treatment program, that in many of our existing centers, they are turned 
away, because we don't have the resources. And a week later, a month later, sometimes 6 
months later, these people are going to be out on the street, using these drugs, they're 
ideal candidates for transmission to the heterosexual community; just strikes me as 
crazy given the nature of this epidemic, that there is a war declared and to ensure that 
people who want to get treatment, do in fact get treatment. And I'm curious what-- am 
I overstating the issue from the Department's standpotnt and what steps are you taking 
to make sure that someone who is in this condition who wants treatment, gets treatment 
immediately and doesn't have to wait weeks or months, and in the meantime maybe infec-
ting themselves and others. 
DR. KELTER: l s ould leave most of that discussion to folks from the Department of 
Alcohol and Drug programs who have a much more working knowledge of what the wait and 
backlog is and what the demand has been for treatment. I do know that they have changed 
their regulations in the past year to permit easier access to Methadone programs for 
some clients who want to detoxify. But beyond that, I'm not as conversant in the 
details as I would like to be to answer your question. Whether we're at the point where 
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New York was 5 years ago is a terrific and important question whose answer we are in the 
process of developing with seroprevalence studies that involve the Department of 
Alcohol and Drug and local drug programs. We are hopeful that we're not quite where New 
York was 5 years ago; we're hopeful that the patterns of drug use and heroin addiction 
in California are not the same as they are in New York, and Newark, New Jersey, and 
Miami, and that we can be effective in teaching people who use drugs how not to transmit 
virus. But it is very difficult in any community to be rather open and forthright about 
discussions involving IV drug use; there are folks in every community who are, to 
some extent, rightfully upset about suggestions that if you follow certain practices 
that drug use is sort of O.K. in the point of view of AIDS transmission. And that was 
what I was referring to earlier when I said we are still trying to figure out what 
mixture of methods and information is really effective in curtailing spread of the virus 
in the drug using population. 
CHAIRMAN HART: Course, Methadone is an accepted standard for the most part, it's 
already in law. I guess what concerns me, and I want to be fair -- I know you're here 
and Dr. Kizer is not but, if the testimony is accurate, that the way this is most 
likely to be spread to the heterosexual community, and from a general population 
standpoint, there's probably no greater public health interest or political question, 
that how can we avoid the spread of this to warn people and since most people are 
heterosexual not homosexual, it's an awfully key question. And what you're saying is, 
"Well, I don't really know the answer to that, you have to talk to the people in Drug 
and Alcohol." That's of concern to me, and one of the reasons why this commit tee 
was established, is to try and deal with, you know, all the different nitches in the 
bureaucracy . If we're dealing with something as fundamental as that, and the Department 
of Health Se rvices doesn't have an answer to that, we have to go to some other bureau-
crati c agency to · find it. It 1 s distressing to me as to whether or not we have an 
overall strat egy , do we have an overall person in charge; or did, sort of, different 
I 
aspects of the problem get so compartmentalized, that we don't have a general in charge. 
DR. KELTER : I may have not made quite clear what I was trying to say. I was 
referring you to t he Department of Alcohol and Drug Abuse for statistics about how long 
t he wa i ting list is in Methadone programs, etc. I think it's quite fair to say, there 
is an overall plan , and that is to identify those pockets of drug use in California with 
a high seropreva l ence, and focus our education and intervention efforts in those 
areas . It's not going to be the same risk -- you ' re not going to have the same risk for 
i nfection in Fresno and Redding as you will have in San Francisco and Los Angeles, 
probably, but we're still collecting data to try and prove that. We will never have, 
and never agreed to provide, I'm sure, the resources that are necessary to educate 
every man, woman, and child in the United States about something that may or may not be 
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a great risk to them. And unless that statement is misinterpreted ••• 
CHAIRMAN HART : That's not what I'm saying. I'm saying let's deal with the most 
high risk group, the IV drug use, it's a finite number, it's something that -- we would 
find those resources to be a tremendous pay-off, I would think. 
DR. KELTER: Absolutely. Well, I disagree. We are doing it. We are identifying 
those ••• 
CHAIRMAN HART: We're not doing it, because there's a waiting list. People who get 
turned away and we'll argue over the statistics and you don't know them, whether it's a 
day, a week, or a month or 6 months, but people are waiting substantial periods of 
time. 
DR. KELTER: Well, I think you're assuming that Methadone treatment is an automatic 
cure for the passage of hepatitis or of human immunodeficiency virus from person to 
person. I don't know that that's the case. In fact, it clearly hasn't -- hepatitis B 
transmission has not effectively been interrupted by any reliable effective method in 
the drug using community. And we are going to have to be very novel and very insightful 
to find the way to prevent this virus transmission in a community where previous virus 
transmission has not really been possible. 
CHAIRMAN HART: The last question I had was Dr. Flynn was talking about the skilled 
nursing care issue. Is the Department of Health Services involved or concerned about 
issues of cost upon people who are sick or going to be sick, and how do you -- do you 
think Dr. Flynn's suggestions, for example, that people ought to be able to go into 
skilled nursing homes, maybe there ought to be a differential rate given the severity of 
the illness; is that an issue that the Department is exploring? Do you have a solution? 
DR. KELTER: We don't have a solution yet, but we,are certainly exploring it, and 
that's one of the primary purposes for our pilot care programs. I should remind you and 
the committee that when we first made funds available in the pilot care setting to 
institutions to show us how much it costs and how costs can be estimated and reduced to 
take care of AIDS patients in a skilled nursing facility setting, we got no bidders, 
because there were virtually no skilled ·nursing facilities caring for AIDS patients 2 
years ago. And it's very difficult to make these demonstrations when the activity is 
not taking place in the private sector. I should also respond by reminding the commit-
tee that while there's a shortage of skilled nursing facilities for AIDS patients, there 
is an overall s hortage of skilled nursing facilities for all patients in California; 
and, I think, any attempt we made to make beds available for AIDS patients would 
have to be done in a way that we were satisfied would not displace other patients who 
also need skilled nursing facilities. 
Whether a differential rate would accomplish that purpose, I don't really know. We 
have pilot studies underway, we have the waiver going to the federal government to allow 
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more out-of-hospital care, we have cost-of-care contractors -- University of California 
and others , to try and advise us on this very question. We've also written reports and 
estimates of future medical care costs from the Department; I 1 ll refer you to the 
s o-ca lled quantitative analysis, which was prepared in 1986, and which is, I'm sure, in 
your possession and if not, we'll be happy to make it available to you, which outlines 
t he effect, precise l y, on Medi-Cal and from the acute care and the skilled nursing point 
of view. 
CHAIRMAN HART: Thank you very much, Doctor. Any questions, Senator? 
SENATOR DOOLITTLE: Are you familiar with the Colorado approach to HIV and the AIDS 
problem? 
DR. KELTER: I've heard a fair amount about it; I was at the Centers for Disease 
Control within the last couple of weeks and heard a fairly extensive discussion by the 
Colorado officials. 
SENATOR DOOLITTLE: I think that might be something that could be a benefit to 
this Committee, to have them come, 'cause a lot of the underlying assumptions and 
comments made about particularly mandatory testing, which basically my bills are not, 
although I favor a very greatly increased approach to testing, but the underlying 
assumption is that people would avoid seeking 1nGdical treatment and I think the statis-
tics in Colorado are, despite the fact that I think all the cases they deal with that 
are HIV positive are reportable, that they do maintain confidentiality, and I don't mean 
the sort of confidentiality we have in California, which is, I think, overly strict, but 
the cases are handled with sensitivity and people don't seem to be avoiding medical 
treatment and indeed I think a number of the assumptions about this are proven false by 
that example in Colorado. I just wondered if -- you know, what did you hear in Atlanta, 
and how do feel about that? 
DR. KELTER: I didn't hear a blow-by-blow description of their program or of their 
st atute; I did hear a point of view which was that discrimination against people with 
infection a d people with certain lifestyles is not a terrific problem in Colorado. And 
it was quite a different discussion from the discussion that, I think, would pertain to 
Cal.i fornia where there have been a number of reports of a real life calamity for people 
whose Lifestyle or whose infection status has been revealed. So, I guess what I got 
from that interchange was perhaps, if you will, a bit of a different world view between 
Ca l ifornia and Colo rado about what the reality is for people who maintain lifestyles and ____ _ 
people who maintain behaviors that would put them at risk for HIV and actually get them 
infected for HIV. 
SENATOR DOOLITTLE: Yeah, but are you comparing the same thing there, because one, 
we're talking about reporting to the appropriate health officials and the examples that 
I think that you're talking about here, where word has gotten out somehow to the general 
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public that somebody has HIV or AIDS. 
DR. KELTER: Well, with all due respect, Senator, both in the area of HIV infection 
and in the area of hazardous waste control, and the area -- several other controversial 
areas; I know when I go into a community, I'm not really regarded as the Public Health 
Official or the Doctor or as the Epidemiologist. With apologies to Louis XVI, "L'etat 
c'est moi;" I am the state, and whether I'm ••• 
CHAIRMAN HART: Louis XIV. 
DR. KELTER: Sorry. (laughter) Apologies ••• you've seen one Louis, you've seen them 
all. (laughter) 
I'm regarded as someone from the state; and whether it's my Department, or someone 
else's Department, or someone else's mistake, or someone else's slip-up that allowed one 
of these life calamities to take place, it's still on my head; it's still, as the state, 
my responsibility. And because of that, I know I and I know many other health officers, 
approach this problem very gingerly and try to maintain this balance of testing and 
trust that is so difficult to maintain. 
SENATOR DOOLITTLE: I just can't believe that California would be fundamentally 
different in its reaction than the people of Colorado to this problem. If anything, 
one would expect the reaction would be more inte~e in Colorado than here. 
DR. KELTER: Well, they've been different so far. 
SENATOR DOOLITTLE: Well, I think the matter -- we need to look into, perhaps, a 
little further. 
CHAIRMAN HART: Thank you very much, Doctor, and for your testimony. 
This concludes our hearing. I do want to mention that the Committee was scheduled 
to have its next hearing in San Francisco to focus on the treatment issue, to actually 
visit some AIDS treatment centers, and to talk to people who are health care practition-
ers that are involved in the day-to-day care of AIDS patients. Unfortunately, the date 
of that hearing is the day the Governor has called the Legislature back into Special 
Session. And, so, we're going to have to reassess our dates and see if we can still 
have that hearing and -- but the date will probably have to be changed and we'll advise 
anyone who's so interested as soon as we get our act together. 
Thank you all for attending and this hearing will stand in adjournment. 
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